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INTRODUCTION 
Fildes, in ІСЙО (13), in a paper entitled "A Rational 
Approach to Research in Chemotherapy" postulated that the 
action of many antibacterial substances may be explained 
in terms of interference with an essential metabolite. 
An "essential metabolite" was defined as "each state in 
any synthesis necessary for growth, without which, either 
synthesized or supplied from outside, growth cannot occur". 
So it was suggested that the action of oxidizing dyes, 
such as thionine and methylene blue, on the bacterial cell 
may be to oxidize (an) essential metabolite(s) which the 
cell requires in a reduced state in order to function. No 
growth will occur until the essential metabolite is again 
reduced. The discovery by Woods (ΊΟ) that ρ.aminobenzoic 
acid (PABA) (I) has a powerful antagonistic effect against 
the bacteriostatic action of sulfanilamide (IIa) and the 
observation that a proportionality exists between the 
concentration of sulfanilamide and the amount of PABA, 
needed to overcome bacteriostasis, caused by the former, 
led to an extension of the Pildes theory. Due to the 
HiNCKu ^ С К 0 
^ OH ^ YiHR 
I PABA II, lb R . Η 
ОН Н л = ÇOOH 
N^YN^CHrNQcowCH 
111 folic acid 
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structural similarity of ΡΛΒΑ and sulfanilamide, V/oods 
(ΊΟ) and Woods and Kildes (Ή) postulated that sulfanil­
amide and its derivatives (II) сопрет о with FABA, an 
essential metabolite, for ito acsr>c;ation wJth an enzyme 
necessary for bacterial growth. 
Although some insight into the biological role of PABA 
was obtained not until ig'ib with the discovery of folic 
acid (III) (1), the theory of Woüds and Fildes was con-
firmed by a number of workers. Rubbo and Gillespie СЗІ) 
were the first to show PABA to be an essential metabolite 
for microorganisms. Organisms which do not require PABA 
as a growth factor synthesize the metabolite themselves 
(23). Also the obedience to the law of mass action of 
sulfanilamide and its derivatives in relation to PABA, 
was experimentally verified (38, hj>, li¡l). 
One phenomenon remained puzzling fron the outset. Deriva-
tives of sulfanilamide obtained by substitution at the 
-SOpNH- group, which were more active than sulfanilamide 
itself, seemed to be chemically ]ess аііке PABA than is 
sulfanilamide. However, the physico-chemical explanation 
given by Bell and Roblin (5) and others 16, 10, 32, 33) 
showed that the introduction of a substituent into the 
-SOjNH-- group may optimalize the electronical properties 
of the -SOjNH- group even so that they are more akin to 
the properties of the carboxyl group of PABA. 
Since the role of РАБА in biological systems was still 
unknown, objections against the theory of Woods and 
Fildes could be formulated. So Henry (ΙΌ, from critical 
evaluation of the experimental evidence and of the various 
theories, pointed out that all biological methods to show 
that PABA is an essential metabolite, are subject to doubt. 
He believed there was clear evidence to show that it is 
not necessary for an antagonist to be a normal component 
2 
of the biological system in order to overcome the action 
of an inhibitor. However, the recognition of PABA being 
an important part of the growth factor for Lactobacillus 
савег, i.e., folic acid (11, and the observation that 
folic acid may antagonize non-competitively the sulfon­
amide inhibition, and that microorganisms which need folic 
acid as growth factor, are not inhibited bv sulfonamides 
(21, 22, 39» ^2), disproved tne last objections against 
the tneory of Woods and Fildes. 
Folic acid appeared to be an essential vitamin for all 
higher organisms and must be provided preformed m the 
diet (for review see. Stokstad, 36). The cellular function 
of folic acid (in its tetrahydro forrr), both in bacteria 
and higher forms, is as a coenzyme (CoF) in enzyme systems 
for the transport of units containing a single carbon atom 
from one molecule to another (15, 37). This happens with 
the carbon atom at one of three oxidation levels: formate, 
formaldehyde or methanol. The one-carbon unit released 
10 from the donor becomes combined with the N atom (of the 
PABA residue) or with the N aton, or forms a ring between 
10 S 
the N and the N' atom. This compound reacts with an 
acceptor and transfers the one-carbon residue to it. The 
one-carbon transfer reactions are essential steps in the 
synthesis of several amino acids, purines and thymine. The 
folate coenzymes may be also important for the initiation 
of protein synthesis (11). Since inhibition of the incor­
poration of PABA into folic acid creates a shortage of the 
coenzyme(s) and thus a shortage of essential constituents 
of the cell, it is easy to see why sulfonamides have such 
a drastic effect on growth of organisms which synthesize 
their own folic acid. 
In the past decade, the biochemical pathway of folate syn­
thesis in several microorganis*ns as well as in plants, 
became elucidated (8, 27, 28, 35) (see 1.1, for detail). 
It was shown that sulfonamides inhibit competitively the 
folate synthesis in cell-free systems and that their in-
hibitory activities are proportional to their antibacterial 
activities (7, 25), which ultimately proofs the theory of 
Woods and Fildes. 
A structural similarity between the -SO-NH- group of the 
sulfonamides and the -COOH- group of PABA, at first sight, 
seemed not so obvious. Therefore, in the past, numerous 
derivatives of PABA have been synthesized and tested for 
their antibacterial activity (28). Besides the tuberculo-
static p.aminosalicylic acid, however, none of these com-
pounds are useful as chemotherapeutic agent, because the 
compounds are either inactive, very weak PABA antagonists 
or they may even substitute for PABA as a growth factor 
(3, 19, 24, 26, 34, 'tS). Nevertheless, it seemed worth-
while to pay some more attention to derivatives of PABA 
as potential PABA-antagonists, because of the following 
considerations : 
1) PABA derivatives are structurally more related to PABA 
and therefore it might well be that they become incorporated 
into a folate analog. The latter compound may interfere 
with the one-carbon transfer reactions and causes in that 
way lethal synthesis (2). 
2) A phenomenon, which may accompany controlling bacterial 
infections, either by chemotherapeutics or antibiotics, is 
the development of resistance. One possibility for the 
microorganism to gain resistance against sulfonamides is 
to alter the membrane permeability for these drugs (29). 
If PABA-antagonists with a close structural similarity to 
PABA could be made, this way of resistance development 
1» 
might well be overcome. This is the more so for those 
microorganisms which need PABA as growth factor, since it 
is not unlikely to assume that these organisms will have 
an active uptake system for PABA, which, probably, also 
will transport these PABA analogs. 
3) For rodential as well as for human malaria, it is shown 
that PABA is an essential factor for the development of 
the malaria parasite in the host (16, 18, 20). PABA-
-antagonists, such as Ί,4'-diaminodiphenylsulfone (DDS) 
and sulfonamides are, although only weakly, effective 
against malaria, and their antimalarial activity can be 
antagonized by PABA (4, 9, 30). Also inhibitors of dihydro-
folate reductase, such as pyrimethamine, are useful in 
malar.i^therapy (Ί, 9, 17, 30). Moreover, dihydrofolate 
reductase could be isolated from Plasmodium berghei (12). 
These facts, taken together, indicate that the malaria 
parasite synthesizes its own folate, and that PABA, the 
central part of the folate molecule, has to be obtained 
from outside. Nevertheless, sulfonamides are only weak 
antimalarial chemotherapeutics. A reason for this may be 
a restricted permeability through the cell-wall of the 
parasite. As stated in 2), PABA-antagonists which are 
structurally closer to PABA than sulfonamides, might over­
come the cell-wall barrier. 
The aim of the investigation, presented in this thesis, 
was to get more insight into the physico-chemical and 
structural requirements necessary for a compound to inter­
fere with the PABA-converting enzyme system. 
In order to eliminate permeability effects and/or bio-
modification by bacterial metabolic processes, the inter­
action of the potential PABA-antagonists with the PABA-
-receptor was studied on the cell-free H5-pteroate syn-
5 
thesizing system. 
The iiifonr.dtion obtained might give clues to the design of 
compounds with strong inhibiting properties for the "folate" 
synthesis. 
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I. THE II2-PTEROAÏE SYNTHESIZING SYSTEM 
1.1 THE BIOSYNTHESIS OF TETRAHYDROFOLIС ACID (THF) 
The pathway for the biosynthesis of 7i6-dihydrofolic acid 
(DHF), as occurs in microorganisms and plants, and the 
formation of THF thereof, which latter reaction presumably 
occurs in all living material, are represented in Fig. 1.1. 
2-Amino-h-hydroxy-6-hydroxymethy1-7,8-dihydropteridine 
(H.-pter), I, is formed from guanosine triphosphate (GTP) 
in several steps. These steps are successively; removal of 
the carbon 8 of GTP as formic acid (7, 8, 30), ring closure 
between the pyrimidine- and the D-ribose moiety resulting 
in the formation of dihydroneopterin triphosphate (8, 16, 
23) , dephosphorylation of the latter and, finally, removal 
of the two outer carbon units of the 6-(1,2,3-trihydroxy-
propyl) side-chain (8, 16, 23). 
Hp-pter, in turn, is pyrophosphorylated at the 6-hydroxy-
methyl group (compound II) by the enzyme H2-pteridine-
-CHpOH pyrophosphokinase (24, 31) (Fig. 1.1, step 1) with 
ATP as the pyrophosphoryl donor (18, 20, 21, 2k, 28, 29, 31). 
2+ 2 + Mg (Μη (20)) is needed for the enzyme to function. This 
pteridine (II) is converted to 7,8-dihydropteroic acid 
(Hp-pteroate ), III, by coupling with ρ.aminobenzoic acid 
(PABA). The reaction is catalyzed by the enzyme Hp-pteroate 
2+ 2 + 
synthetase (2h, 31), and requires Mg (Μη (20)) as metal 
activator (18, 20, 21, 24, 28, 29, 31) (Fig. 1.1, step 2). 
The other product of the reaction is inorganic pyrophosphate. 
Hp-pteroate is enzymatically transformed to 7,8-dihydro-
folic acid (DHF), IV, by condensation with L-glutamic acid. 
ATP is used as coenzyme (6, 13) (Fig. 1.1, step 3). DHF is 
reduced to THF, V, (Fig. 1.1, step Ό by the enzyme dihydro-
Burg and Brown (8) postulate that dihydropterin tripkoe-
phate is formed from GTP in a one-step reaction, catalyzed 
by the enzyme GTP cyclohydrolase. 
10 
H N ^ N I 
PPPO^J j 
біГЬн 
GTP I 
WHa' CO-Glu-
PAac, PPi< 1 - ι 
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**і* 
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COOH 
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- N^Y 
мнАцЛг
1
* ж 
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Η 
CHiNH' CO-Glu 
Fig. 1.1: Bi o synthetic al pathway of DHF (IV), ocourring in 
microorganisms and plants, and its formation to THF (V). The 
points of application of compounds, which interfere with the 
biosynthesie of THF are indicated by blocks, mm , PABA 
antagonists. C2ZI , Folate antagonists. 
folate reductase. Either NADPH or NADH can be used as hydrogen 
donor in this reaction (3, 14, 32). Dihydrofolate reductase 
also catalyzes the formation of THF from folic acid, although 
the latter compound has a lower turnover rate (3, 12, 14, 32). 
DHP (IV) may also be formed directly by offering ρ.aminobenzoyl-
-L-glutamic acid (L-PABG) as substrate to the enzyme H--
-pteroate synthetase (Fig. I.l, step 2') (6, 13, 20, 21, 25, 
27, 29, 31)· However, it does not seem likely that this step 
normally occurs, since a) up to now no enzyme system is found 
which condenses PABA with L-glutamic acid (6, 13), and b) 
for the H2-pteroate synthesizing systems, originating from 
different sources, PABA possesses a considerable greater 
affinity for the enzyme Hp-pteroate synthetase than L-PABG 
(6, 20, 21, 25, 29, 31). 
As already summarized in the Introduction, THF is an essential 
metabolite for the living cell. The compound is a precursor 
for coenzymes which are involved in one-carbon transfer 
reactions. In Fig. 1.2, a schematic representation is given 
for some of the principal biological systems, THF is involved 
with (9, 15, 32). 
DHF 
THF 
one-carbon 
donors « 
("active"-formate, formaldehyde methanol 
^· thymidilate 
Pa 
^•purine nucleotides 
Pb 
^•methionine 
Pc 
• serine 
Pd 
Coenzyme F 
Fig. 1.2: Diagram summarizing the cellular functions of Co­
enzyme F. Pa etc., are precursors of ultimate products. 
A deficiency in THF, either induced artificially or by a 
metabolic defect, causes a shortage of factors, which are 
essential especially for growing cells. 
Up to now two tools are available to interfere with the bio­
synthesis of THF: 
A) Competitive antagonists of РАЗА: These compounds compete 
with PABA for the active site on the enzyme Hp-pteroate 
synthetase. In that way the synthesis of Hp-pteroate 
(Fig. 1.1, step 2), or, in case L-PABG is used as substrate 
the synthesis of DHF (Fig. 1.1, step 2'), is blocked (5, 20, 
21, 29)· Since lower forms of life only, and plants, are in 
possession of the folic acid synthesizing system, PABA-
-antagonists are species-selective in their action. The re­
presentatives of these compounds, used in the treatment of 
various infectious diseases, are the sulfonamides. 
B) Folate antagonists: These compounds compete with DHF for 
the enzyme dihydrofolate reductase (1¿J, 22, 32, 35, 36). The 
affinity of the classical folate antagonists (aminopterin 
and methotrexate) for dihydrofolate reductase is so high 
(about 10 times higher than that of DHF), that they have 
been designed as non-reversible antagonists (l^, 32, 35). 
Since these compounds not only show this extreme affinity 
for dihydrofolate reductase of microorganisms but also for 
the enzyme of higher animals, including man, they have only 
limited value in therapy. Only, by lack of better therapeu-
tics, they are used in the treatment of leukemia (1, 1*0 . 
The development, in recent years, of more selective inhibi-
tors of the enzyme dihydrofolate reductase, e.g., pyrimetha-
mine, trimethoprim, ρ.butyl-phenyltriazine, has made this 
biochemical step more accessible to rational therapy (2, 11). 
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1.2 EXPERIMENTAL PROCEDURES 
1.2.1 THE ESTIMATION OF THE CELL-FREE SYNTHESIS OF H2-PTER0ATE 
Two assay methods are known to determine the enzymic activity 
of the Hp-pteroate synthesizing system: 
1) A microbiological assay. The product, formed enzymatically 
from the pteridine cosubstrate and PABA (or PABA analogs; e.g., 
L-PABG), i.e., H.-pteroate (or DHF), is determined as a growth 
factor for Streptococcus faecalie (ATCC 8θΌ) (6, 26). This 
assay method is used throughout this study to determine the 
folate activity of the pteroate compounds formed. 
1Ί 
2) A radioassay with C-labeled PABA. After separating the 
Ik 14 
product, ( OHp-pteroate, and the substrate, ( C)PABA, by 
appropriate technics, the former can be determined quant­
itatively by means of liquid scintillation counting (.19, 24). 
This assay method is generally employed to determine the 
cell-free turnover of PABA and the influence thereupon of 
(potential) PABA-antagonists. 
In the following subchapters, a detailed description is given 
of the respective assay methods. 
1.2.1.1 Microbiological assay 
The general procedure was as follows: Samples for assay 
were withdrawn from the reaction mixtures and diluted with 
distilled water in such a way that four dilutions (1, 3/10, 
1/10, 3/100) of the original solution were obtained. Of these 
dilutions 0.1 ml was added to assay-tubes, containing 5 ml 
of the double strength Difco Folic Acid Assay Medium 
supplemented with 0.5 ml 2-mercaptoethanol per liter. The 
volume in the tubes was filled up to 10 ml by addition of 
distilled water containing 1.2 g vitamin-free casamino acids 
(Difco) per liter. The tubes were autoclaved at 120° for 
11) 
15 rain. After equilibration at 37°, the assay tubes were 
inoculated with one drop of an 8 h culture of Streptococcus 
faecalia grown in the folic acid assay medium containing 
1 ng folic acid per ml. The assay tubes were incubated for 
20 - 2^ h at 37 and the growth was assayed as turbidity 
measurements with a Coleman Model 9 nephelometer. Folic 
acid standards were used in each assay. 
1.2.1.2 Radioassay 
Since the microbiological assay, as described above, is less 
accurate and implies a lot of work, Okinaka and Iwai (19) and 
Richey and Brown (2Ί) developed a radioassay making use of 
C-labeled PABA. The formed C1 C)H0-pteroate is separated 
1Ί from ( С)PABA by means of paper chromatography. For routine 
use, however, this method is still somewhat time-consuming, 
especially with respect to the application of a number of 
samples upon the paper. Therefore, the radioassay was nod-
ified in such a way, that product and substrate could be 
separated more rapidly (33). This separation is based on 
the extractability of PABA by diethylether at the appropriate 
pH value, 3-8 (4). 
Procedure: 
Preliminary experiments showed that at pH 3.8 no formation 
of Hp-pteroate occurred. Hence, the enzyme reaction could be 
stopped by adjusting the pH of the reaction mixture to 3.8. 
This was performed by the addition of 1.5 ml of a concentrated 
citric acid - phosphate buffer, pH 3.8, to the reaction 
mixture (0.5 ml) (33). Unlabeled PABA (1 mM) was added to­
ll) 
gether with the buffer in order to exchange ( C)PABA which 
may be adsorbed to protein and/or to the inner-wall of the 
reaction vessel. Of the final mixture 1 ml was diluted 1 : 1 
15 
with water and extracted vjith fou." 5 -Til portions of ether 
by shaking on a rotary shaker for 10 min. Of the extracted 
water layer 0.2 ml were put into counting vials containing 
0.5 ml water f-nd 10 ml Fack-ird Insta-gel. The vials were 
counted in a Packard Tri. Carb. liquid scintillation counter 
model 3380. 
1.2.2 THE PREPARATION OF CELL-FREE EXTRACTS OF E.COLI 
To study the incorporation -and the inhibition thereof- of 
PABA into Hp-pteroate, three possibilities are at hand, 
concerning the cell-free Hp-pteroate synthesizing system: 
1) A system dealing only with the enzyme Hp-pteroate synthe­
tase (see the solid-line square in Fig. 1.1). This system 
necessitates the availability of the pyrophosphoric acid 
ester of H?-pter (compound II, Pig. 1.1). 
However, the chemical accessibility of this pteridine and 
the ultimate quantity one gets (24, 28, 29; is such, that 
the system, dealing only with Hp-pteroate synthetase, is 
less suitable for routine use. 
2) A system dealing with two separated enzyme preparations; 
enzyme preparation A containing the enzyme Hp-pteridine-
-CHpOH pyrophosphokinase (step 1, Fig. 1.1), and enzyme 
preparation В containing the enzyme Hp-pteroate synthetase 
(step 2, Fig. I.l). The experimental procedure to estimate 
the turnover of PABA, is as follows; after incubating a 
reaction mixture, containing: enzyme A; ATP; Mg and Hp-
-pter, for a fixed length of time, enzyme В and PABA are 
added and the incubation is continued (24, 25, 31)· 
3) A system dealing with an enzyme preparation containing 
the enzyme Hp-pteridine-CHpOH pyrophosphokinase as well as 
Hp-pteroate synthetase (see the dashed-line square in 
Fig. I.l). To estimate the turnover of PABA, a reaction 
mixture containing this enzyme preparation, in addition 
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should contain, h.-pler, ATP, Mg + and PABA (steps 1 and 2, 
Fig. 1.1). 
In view of the fact, that screening a number of compounds 
for their PABA-antagomstic activity implies a lot of routine 
work, the th-^ rd system as described above, is chosen for the 
mvestigatior of the cell-free synthesis of Hp-pteroate. 
1.2.2.1 Tire cell-free extract of Е.соіг В 
ЕескегъсЬга coli В was cultured in a synthetic medium, con­
taining per l^ter of tap-water KH PO^, 6 g, K2HP04.3H20, б 
g, NHjjCl, 2 g, MgSO¡).7H20, 100 mg, glucose, 20 g; and vita-
mm-free casanmo ac^ds (Difco), 10 g. 
Amounts of Ί - 5 liter were inoculated with 50 ml of a cui­
tare of the organism in the logarithmic phase of growth, and 
cultured at 37 with aeration. Cells in logarithmic phase 
were harvested and washed with saline. Approximately 2.5 to 
3.5 g of wet cells per liter v>ere obtained. The cells were 
suspenaed in tns-HCl buffer (0 05 M, pH Θ.0, k ml per g 
of cell-paste) and disintegrated by somcation for 2 - 3 
m m at 0° using a Branson somfier, B-12. After sedimentation 
of the cell-debris by öentnfugation, the supernatant was 
dialysed overnight against 5 liter 0.05 M tns-HCl buffer, 
pH 8.0, at 4 . All subsequent manipulations were performed 
at 4 . A saturated airmoniuir sulfate solution was added to 
the dialysed protein solution to make the latter 30$ satu-
rated with respect to (NH^-SOj.. The precipitate was removed 
by centnfugation and to the supernatant ammonium sulfate 
was added to 70? saturation. The precipitated protein was 
collected by centnfugation and resuspended in 0.05 M tns-
-HC1 buffer, pH 8.0 (5 ml per g 30 - 70% ammonium sulfate 
fractior). The resulting solution was dialysed for 24 h 
against 0.05 M tns-HCl buffer, pH 8.0 (2 changes of 5 1 
17 
bufl'er). Any precipitate was removed by centrifugation and 
the resulting solution was put into vials (in 2 ml aliquots) 
and stored at -20 . No loss of enzyme activity occurred 
within 1 month. 
1.2.2.2 The cell-free extract of E.ooli 273 
The same procedure as followed for the preparation of the 
extract of E.ooli В was employed to prepare cell-free pre­
parations of the PABA-deficient strain of Escherichia coli, 
E.coli 273· (The organism was the gift of Prof.Dr. CG. de 
Haanj Institute of Microbiology, University of Utrecht). 
E.ooli 273 was cultured in the synthetic medium used for 
E.coli B, but which in addition contained 3 X 10~7 M PABA. 
The protein content of the enzyme preparations was determined 
by the method of Lowry et al. (17)· 
1.2.3 CHARACTERISTICS OF THE ENZÏVE SYSTEM OF E.COLI, WHICH 
MEDIATES THE FORMATION OF H -PTEROATE 
1.2.3·! The incubation system 
Since the formation of Hp-pteroate from H?-pter and PABA 
is mediated oy two enzyme reactions (steps 1 and 2, Fig. 1.1), 
the incubation of the enzyme system was performed in two 
steps: a) a first incubation period without PABA, to ensure 
the formation of an initial quantity of the pyrophosphorylated 
dihydropteridine, after which b) PABA was added to start the 
formation of Hp-pteroate (33)· 
The reaction mixtures were prepared to contain in a volume 
of 0.35 ml: 0.5 jumóles ATP; 2 emoles MgClpî 0.5 mg sodium 
ascorbate; 0.1 mmole tris-HCl buffer (pH 8.0); and 20 - 25 
nnoles Hp-pter. The mixture was equilibrated at 37 and the 
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en^ y-ie reaction was started by the addition of 0.1 ml of 
the protein solution. After incubation at 37° for 10 τιιη, 
1 M 
50 ді of a PArìA (( О Р А В А ) solution was added and the 
j-ncubation was continued. 
Reaction mixtures, in which H?-pter failed, served as blanks. 
In case the microbiological assay was used to estimate the 
Hp-pteroate (or I?-pteroate derivatives) forned, the enzyme 
reaction was stopped by addition of 0.5 ml of a hot (90 ) 
solution of sodiur ascoroate (15 mg/ml). After heating for 
additional 5 m m at 90 , tne mixtures were aeprotemized by 
centnfugation. xhe supernatants vere handled as described 
m 1.2.1 
If tie rad^oassay has used, the ^nzyne reaction was stopped 
by addition of 1.3 ml of the citric acid - phosphate buffer, 
pH 3.8 (see 1.2.1.2). 
1.2.3.2 Seme properties of the onzyrre system 
Kaximui enzyme activity was observea _r the logantrmic phase 
of growth (Fig. 1.3). 
The Hp-pteroate synthesizing activity of the crude extract 
and the 30 - 70% ammoniuir sulfate fraction (1.2.2.2) is sum-
nar^zea in Table 1.1. 
Table I 1 
fraction activity 
crude extract 1.5ο 
30-70? ammonium sulfate fraction 3.12 
аоіг гіу гп rimóles H -pteroate formed per 
h per mg protein 
19 
extinction Hj-pterodte 
nmole / h Imi protein 
16 
-12 
Οθ 
0 4 
J» θ 1 2 
time (h) 
Fig. 1.3: Growth of E.coli В and en­
zyme activity. Φ — », growth curve. 
о -- Oj enzyme activity of the crude 
extract expressed as Η2-pteroate formed 
per h per mg of protein. Samples were 
withdrawn at times indicated by arrows. 
As is seen, the fractionation of the crude extract into a 
30 - 70? ammonium sulfate fraction, resulted in an about 
twofold enhancement of the specific activity. 
Fig. 1.4, depicting the radioactivity not-extractable, and 
the radioactivity extractable with ether as a function of 
the time of incubation, is an example of the experimental 
set-up of the radioassay. The radioactivity in the water 
layer increased linearly with the time of incubation. The 
rate remained unchanged for at least 1 hour. The radio-
0 6 -
05-
04-
03-
02J 
Ο ί ­
ο-, 
"\VT 
Λ 
• / \ 
/ ' 
j 
•— 
20 
ч IO dpiii in ether 
I 
210 
xlû dpin in Leiter 
20 • 
. / 
Fig. Ι.Ί: The enzymic formation of 
H2-pteroate in relation to the time 
of incubation. The reaction mixtures 
contained in a total volume of 0.5 ml: 
H2-pter3 25 nmoles; ATP, 0.5 jumóles; 
МдСІ23 2 Mmolesj Na-ascorbate, 0.5 mg; 
tris-HCl buffer (pP 8.0), 0.1 mmole; 
enzyme preparation equivalent to 370 jug 
and PABA 20 nmoles. · — * Radioactivi­
ty (dpm) not-extracted with ether, в — 
radioactivity гетагпгпд in the blanks, 
• — • ratioactivity extracted with 
ether from the reaction mixtures, • — • 
radioactivity extracted from the blanks 
(1000 dpm = 88 χ lO'lZ
 m
ole). 
activity remaining in the water layer of the blanks did 
not change with time. This was also observed when either 
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2 + ATP or Mg were omitted from the reaction mixtures. By 
means of paper chromatography it was controlea that only 
PABA was extracted by ether (33)· 
Some authors reported enhanced folate activity in the blanks 
when the pyrophosphoryl ester of Hp-pter was incubated with 
PABA in the absence of enzyme (19, 20). To see whether a 
chemical coupling, which might be an explanation of the 
observation mentioned above, occurs between both compounds, 
Hp-pter was incubated with ATP in the presence of the enzyme 
for 30 min. The enzyme reaction was stopped by heat denatura-
o 14 tion (5 min at 80 ) and ( С )PABA was added. No significant 
increase of radioactivity remaining in the water layer, 
could be observed (Table 1.2). 
Table 1.2 
Incubation of pyrophosphoryl-H.-pter with ( C)PABA in the 
presence of denaturated enzyme 
incubation dpm 
period (min) blank Hp-pter (50 дМ) 
0 1302 1318 
10 1329 1293 
^5 1271 1364 
The reaction mixtures (560 мд protein) 
were incubated without PABA, for 30 min 
at 37°. The protein was denaturated by 
heat, and PABA (22.3 мЮ was added. The 
incubation was continued for the time 
indicated, after which PABA was extracted 
with ether. 
radioactivity remaining in the water layer. 
The enzymic reaction shows an optimum at pH about 8 (Fig. 1.5)· 
The dependency of the rate of Hp-pteroate synthesis to PABA, 
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H7-pteroste 
nmole/h/mg protein 
3 0 -
2 0 
10 
/ ' " 
/ 
6 0 70 0 0 9 0 ТОО 
pH 
Fig. 1.5'· Dependency between enzyme 
activity and pH of the reaction mixture 
respectively to H^-pter, is shown in Fig. 1.6 and Fig. 1.7-
For both sJbstrateSj an optimu™ is shown with respect to 
the rate of the PABA turnover. This optimum is for PABA 
between 20 - 30 >uM, and for H.-pter between 20 - 40 ліМ. A 
Lineweaver-Загк plot of the velocity us PABA (Fig. 1.6) 
gave an apparent К value of 3 л:М. This is in good agree­
ment with the К value of PABA for the enzyme system of 
E.coli as reported in literature (21), 25). 
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Fig. 1.6: Betation between PABA concentra­
tion and the rate of H2-pteroate synthesis 
(Lineweaver-Burk plot). Й^'Р*67" 6 0 u M · υ = 
nmol Η2-pteroate formed per h per mg protein. 
H^-pteroate - — 
nmole/b /mg protein 
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Fig. 1.7: Relation between Wg'P*61" concen­
tration and the rate of B^-pteroate synthe­
sis. PABA SO MM. 
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1.2.4 THE INHIBITION IUDEX 
1.2.4.1 Introduction 
Applying Michaelis-Menten kinetics (10) to an enzyme reac-
tion; ,. j, 
1) E + S. 1 L ' E S i~E + Í 
the following mathematical expression can be formulated for 
the velocity of the enzyme reaction: 
2) ν - V 
К /S + 1 
m 
In equation 2, V is the maximum velocity of the enzyme reac­
tion, К is the Michaelis constant, representing the 
dissociation constant of the enzyme-substrate complex, 
and S represents the substrate concentration. The reaction 
velocity in the presence of a competitive inhibitor is 
given by equation 3: 
,, . V 
Э'
 V i ' К /S{1 + Ι/Χ.) + 1 
m ι 
In equation 3> Я· represents the dissociation constant of 
the enzyme-inhibitor complex, and I is the inhibitor con­
centration. 
In case the enzyme reaction is inhibited for 50S», equation 
4 holds: 
4 ) υ
ΐ50 = 1/2
 v 
ι».-, is the velocity of the enzyme reaction, inhibited to 
half maximal level by a competitive inhibitor. By substi­
tuting equation 3 for tf-c:n> and equation 2 for υ, equation 
5 can be derived for the ratio of ΐ^ η to S: 
5) Î50/S = v V 1 + v s > 
25 
Here, ¿,.„ represents tne concentration of the comoetitive 
inhibitor, which, at the given substrate concentration, is 
required to inhibit the enzyme reaction to half-maximal 
level. 
The mathematical expression for i.-fs, hereafter referred 
to as "Inhibition Index" (I.I.), shows that for a competi-
tive inhibitor the Inhibition Index represents the affini-
ty of the inhibitor relative to the affinity of the sub-
strate. Further, on condition the substrate concentration 
is high in relation to Κ , the Inhibition Index should be 0
 m' 
a constant. So the Inhibition Index is a useful biological 
parameter to correlate compounds which act as competitive 
inhibitors. 
The rate of an enzyme reaction in the presence of a non-com­
petitive inhibitor, on condition that the enzyme-inhibitor-
-substrate complex does not lead to product formation, is 
represented by equation 6: 
1 V i ' К /s(l + Ι/λ.) + I/K. + 1 
m г г 
From this equation it can be derived, that in case the rate 
of the enzyme reaction is inhibited to half-maximal level, 
the concentration of the inhibitor should equal K. (eq. 7): 
7) Ho = Ki 
Since it is not a priori that various non-competitive inhi­
bitors possess the same receptor site on an enzyme, this 
parameter cannot merely be used to correlate structure to 
activity of these compounds. 
Since two substrates are involved in the reaction catalysed 
by H2-pteroate synthetase, enzyme kinetics are not as simple 
as described above. 
Three situations can be formulated concerning the reaction 
It ie to note, that Х
г
· normally represents a true affinity, 
whereas K
m
 may include also &2 (equation 1) (10). 
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sequence between the enzyme and the substrates: 
A) PABA interacts with the enzyme-pteridine complex, 
B) the pteridine substrate interacts with the enzyme-РАБА 
complex, and 
C) situation A as well as D simultaneously, may occur. 
A: 
The following reaction schemes can be written in case PABA 
only interacts with the enzyir.e-pteridine complex: 
k1 S .E 
8) S1 • Ε η=Ζ ES1 Χ, = -щ 
к
п
 к ES..S 
9) ES1 + 5 2 ^ ES1S2 -JU E + Ρ К2 - -gi-^l 
5. represents the free concentration of the pyrophosphorylated 
Hj-pter; S 2 is the free PABA concentration; E is the free 
enzyme H2-pteroate synthetase; Ρ is the product, i.e., 
Hp-pteroate; K. and K- are equilibrium constants. Applying 
Kichaelis-Kenten Kinetics, which starts with the premise 
that there is a steady state situation and the rate con­
stants k., k_^, fep, and fe_p are large in relation to fe,, 
equation 10 can be derived for the reaction velocity: 
10) υ 
κ
χ
κ2/εχε2 + Κ2/Ξ2 + 1 
If a competitive antagonist of PABA is involved in the en­
zyme reaction, then the equilibrium as presented in equation 
11, has to be taken into account: 
ES .1 
11) ESÍ + I — ESJ K. - -gg-j 
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For the reaction velocity, v., assuming ES.. I does not, or 
only at low rate, lead to product formation, equation 12 holds: 
;
 i ' XX2/ SlS2 + K2/S2(·1 + I/Ki·1 + 1 
From equations 10 and 12, a mathematical expression is 
derived for the Inhibition Index: 
13) i 5 0/s 2 = κί/κ2{ι + x2/s2(i + x1/s1)} 
Like equation 5, equation 13 snows that the Inhibition 
Index reflects the relative affinity of the conpetitive 
inhibitor for the active site of the enzyne. If S. is kept 
constant and S- is high in relation to K?, the Inhibition 
Index should be almost constant. 
B: 
The following equations can be set up in case the pteridine 
substrate interacts with the enzyme-PABA complex: 
Ι Ό E + S2 ;=^ ES2 K2 
E.S2 
ES-
ES .S 
15) ES2 + S j — ESJSJ — E + Ρ K1 - Έ ή ς Λ 
16) E + IszzSSJ ^ = fjl 
17) £1
 +
 S1^ES1I Ч-Ш^Г 
S- is PABA, S- is the pteridine substrate, I is a competi­
tive antagonist of PABA. 
The velocity of the enzyme reaction in the absence and pre­
sence of a competitive PABA antagonist, is represented by 
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equations l8 and 19, respectively: 
18) ν - V 
X1 X2 / S1 S2 + Kl/Sl + 1 
v 
1Э
'
 V i ' K.K?/S.S~{1 + Ι/Κ.ζΙ + S./K\)} + K./S. + 1 1 ¿ 1 ¿ : г 1 г 1 1 
The Inhibition Index is represented by equation 20: 
20) i50/s2 = KiK^/K1K2.S1/{K\ + s1).{i + K 1 / S 1 ( I + K2/S2)Ì 
If S. is high in relation to λ'., equation 20 can be simpli­
fied to equation 21: 
2 1 ) г 52 = lÇq{1 + Kl/Sl^ + X 2 / S 2 ) } 
Further, if it is assumed that the affinity of S. will be 
independent of the (anti)metabolite with which the enzyne 
nas formed a complex (i.e., ES2 or SI), then K'. equals Κ. , 
and equation 21 gives equation 22: 
22) ¿50/S2 = Ki/K2il + X1/S1(l + K2/S2)i 
Equation 22 shows that, if S. is constant and S? is high, 
the Inhibition Index is a constant and reflects the affini-
ty of the competitive РАБА antagonist for the enzyme. 
If it is irrelevant whether PABA or pyrophosphoryl-Hp-prer 
will comoine first witn the епгутг Hj-pteroate syntheta&e, 
then equations 23 up to 29 inclusive, hola true: 
23) E
 +
 5 1 — ES1 X1 = ¿±L 
29 
24) E
 + S2=ES2 K2 -- ^ - 2 
ES-.S. 
25) ES2, S1^ES1S2-^E + Ρ ^- ELSJ­
ES. . S . 
26)
 E S l + S2^ES1S2 — E * Ρ Ц -- j ^ 
27) E * Ι — ΕΙ K. = y : 
гі .5 1 
28) г/ + s. ^ ^ ES. ι к\ = =?-г· 
1 1 Ъ LO .1 
ES. .ι 
29) ESÍ • Τ ^ ^ T χ · · = ^ 
S- is the pteridine substrate, S? is PABA and I is a 
competitive antagonist of PABA. The equilibrium constants 
are mutually related, which is represented by equations 3C 
and 31. 
30) x1.x¿ = x2..iq 
31) K..^ - KV.^ 
Considering the Michaelis-Menten approximations, equations 
32 and 33 can be derived for the reaction velocity in the 
absence and presence of a competitive PABA antagonist, 
respectively : 
32) ν 
K
'±
K2/SlS2 + K2/S2 * K'l/Sl * 1 
30 
^' -Ί.
 =
 Л1Лт/5.5 ,( 1 + І/Л + /'/S .(1 + l/K' ' ) + ÍÍ'/5. + 1 
The InribiLion Index is repfcbentca by equdtici З1· 
r
">U? г. 2 1 1 Í, £ ¿ J.1 ¿ с 
i.2 Ξ. >·» л', then 2qudti(^ З^  сап ЬР cimpliíied to eqaaticn 35: 
35) г
ь 0/5 2 = JV¿'/A¿C1 + ^\IS¿ + X|/S1Í1 + X?/S2)} 
Also uhis equation s'-ov.s t^at the ^nhih^t^^r Ird»/ is ал ex-
oression cf th? aíi'j.nity of '"he ahib^tor relative "oo ti э 
afí-in-ty oí1 the substrate (i.e , PASA). 
1. 2 .',. 2 T"e est_nation of tne Inmb^^xTn Z^dex 
To estinat ^  the jnhibitir-n ^ndex, ccl^-ir^e -Ip-pt^ rcate 
synthtrSiS was folloi\ea in tna presence о^  ^псгеаыпь anounts 
of the PABA-antagoiist. ""he « ..ihib^ ticn i^ r.^ -Dteroate syn-
tnesj.s was plotted us the ioginthm -f t-ie inhio^tor con­
centration, resjlting in a b^gmcid зиг/е, anc „„^ was 
est-natea by interpolation. 
?roceaure 
f о the reaction mixture, — -onta." д. η Б Π a о-апе of 0 Λ "Ί. 
AT?, C o лпоіез, MgClp, 2 дпоіеь, • a-ascorbate, 0. S πις; 
tris-hCi buffer (pH 6.0), 0.1 r.ncles, 4 -pter, 20 - ¿5 
птоіес, ard enzyne preparation — , wn-Ch was incubated for 
10 run Ά"- 37°, 50 κχ\ of a solution of the inhibitor and 
lí 50 да! ci a ( C)PABA solution were idded, whereupon the 
incubation was continued. 
All experiments were run m duplicate. 
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Fig. 1.8: Plot of % inhibition (I) of 
Η2~pteroate synthesis vs the logarithm 
of the sulfathiazole ooncentration at 
different PABA concentrations. 
Δ — Δ, PABA 10.9 uM (I.I. - 0.Z3); 
о — o, PABA 21.9 Μ'Ί (I.I. = 0.3?)j 
• — Φ, PABA 28.8 MM (I.I. = 0.34). 
In Fig. 1.8, an example is given for the determination of 
the Inhibition Index. The % inhibition of the Hp-pteroate 
synthesis, caused by increasing amounts of sulfathiazole 
at different PABA concentrations, is plotted as a function 
of the logarithm of the inhibitor concentration. Inter­
polating for 50% inhibition and dividing the found inhi­
bitor concentration by the substrate concentration, gives 
the relative affinity of the inhibitor, expressed as 
Inhibition Index. As can be seen from the values, the mag­
nitude of ¿en/s remains constant. 
As is shown by the data given in Table 1.3, the Inhibition 
Index is independent of the Kp-pter concentration. 
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Table 1.3 
The Inhibition Index of sulfathiazole at different H?-pter 
concentrations 
H2-pter (wM) I.I.* 
30 0.34 
40 О.ЗІ 
60 О.32 
120 0.35 
I.I. means Inhibition 
Index. PABA eoncentration 
in all cases was 21.9 juM 
Using the radioassay to estimate the cell-free Kp-pteroate 
synthesis, — and the inhibition thereof — , it should be 
recognized, that, unless corrections are made for the 
dilution of the radioactivity, unlabeled РАБА will manifest 
14 itself as a conpetitive inhibitor of the ( C)H2-pteroate 
synthesis. 
In Fig. I.9, a Dixon plot is given of the inhibition of 
1 il ( OH.-pteroate synthesis by unlabeled PABA. The "К ." ¿ t 
value thus obtained is 2.7 AIM. This value fairly agrees 
with the К value (2.8 JUM) calculated from these curves, 
m 
and with the К value obtained from Fig. 1.6. 
m 
This fictive inhibition may be involved in cases in which 
PABA-derivatives, as potential inhibitors, are studied which 
may, either by chemical or by metabolic processes, release 
free PABA. 
An example of this is given for procaine (8-diethylamino-
ethyl-p.aminobenzoate). Procaine seemed to inhibit cell-
-free Hp-pteroate synthesis. Its inhibitory activity, 
however, increased when the compound was incubated with 
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Table 1.1 
li 
"Inhibition" of ( OHp-pteroate synthesis by procaine in 
relation to the preincubation period of procaine with the 
cell-free system. 
Tiire of incubation (mn) % Inhibition of 
ol procaine with the sys- I-2"Pteroate 3У П" 
tem froir nhich Ι 2-ρΐβΓ thesis in the 2 n d 
and PABA were onitteda) incubation period13 ) 
0 12 
15 23 
30 13 
15 56 
a) Reaotion mixtures (520 мд ргоіегп) were as des­
cribed m section 1.2.3.1. Procaine, 1 mM. 
b) H2-pter (40 мЧ) and VABA (22.3 мИ) ¿ere added 
after the first incubation period and the incubation 
was continued for 30 mm. 
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6 6 10 
RABA (^ M J 
Fig. I.У: ( СÌH^-pteroate synthesis in the 
presence of increasing amounts of unlabeled 
FABA (Dixon plot). » — Ф, (^^CÌPABA 14.4 uM; 
о — о, (14CJPABA 7.2 мМ. υ = nmole (14с)Н
г
-
-pteroate formed per h per mg of protein. 
the system before rip-pteroate synthesis was started (Table 
1.4), indicating that hydrolysis of the PABA-ester occurred 
(34). 
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II STRUCTURE-ACTIVITY RELATIONSHIPS 
II.1 SULFONAMIDES 
11.1.1 INTRODUCTION 
Bell and Roblin (10) showed the existence of a parabolic 
relationship between the antibacterial activity and the 
1 
acid dissociation constant of N -substituted sulfanilamides. 
To explain this observed relationship, they evolved a theory 
which in its simplest form states: "The more negative the 
1 
-SO?- group of an N -substituted sulfanilamide derivative, 
the greater its bacteriostatic power". 
This statement was principally based upon the Woods and 
Fildes theory (see General Introduction). Bell and Roblin 
reasoned that for a sulfonamide to be absorbed into an 
enzyme system competitively with PABA, it should resemble 
PABA in its geometrical and electrical characteristics as 
closely as possible. Since the carboxyl group of PABA 
(pK - 4.68) at physiological pH (about pH = 7) is 
dissociated for more than 99?, the PABA ion should be the 
active form. Hence, a structure in sulfonamides that 
approximates the PABA ion, should be responsible for the 
PABA antagonizing property. Bell and Roblin pointed out 
the similar geometrical relationship between the PABA ion 
and a sulfonamide (Fig. II.1). In the formulae shown, the 
hydrogens of the amino group and the substituted amide nitro-
gen are out the plane of paper. The substituted amide nitroge 
is presumed not to play an important part in the geometrical 
relationship, implying that the substituent R is not involved 
aulfonamide refers to the whole class of N -substituted 
eu Ifanilamides 
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67Â 
«-23Ä_ 
&9Â 
R^N4 
— 24Â., 
р. атгпоЪепгоаЬе sulfonamide 
ion unionized ionized 
Fig. II.1 
in the interaction with the active site on the enzyme sur­
face. In order to approximate the electrical state of the 
carboxyl ion, the sulfonyl group, -SOp-, must gather an 
electric charge equivalent to one electron. Bell and Roblin 
postulated, that, because of the electron-attracting proper­
ty of the -S0?- group, the ionized sulfonamide group, 
-SOpÑR-, which bears a formal charge, will enhance the 
electron density of the -SO,- group. So, the ionized sulfon-
amide molecule will be more active than the unionized. If, 
however, the electron-attracting power of the substituent 
R increases, — which is reflected in increasing acidity 
and hence a greater percentage of ionization at physiolo-
gical pH — , competition is set up with the -SO-- group 
for the electrons of the amide nitrogen. Hence the electron-
-attracting power of substituent R should be in an optimal 
range for maximal activity so that the ptf of the sulfon-
amide is about 6 - ? · 
If, as stated above, the geometrical and electrical proper-
ties of the -SO_-group are determinant for the antibacterial 
activity of the sulfonamides, then a relation between the 
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physico-chemical properties of this group and the anti-
bacterial activity should be expected. However, no relation-
ship between the activity and physico-chemical properties, 
such as S-0 bond force or SO- bond angle, could be observed 
(59). Even more, the net electronic charge on the sulfonyl 
oxygen atom and the sulfur atom appeared to be constant 
despite of the variation in antibacterial activity (18). 
An alternative explanation for the observed parabolic 
relationship was proposed by Breuckner (12) and by Cowles 
(16). They postulated that the sulfonamide molecule in its 
ionized form only, interferes with the PABA-receptor. The 
unionized form, however, only can permeate the cell-wall 
and thus determines the concentration of the drug in the 
bacterial cell. This theory implies that the most active 
sulfonamide drugs are those, which are 50% ionized at the 
pH of the culture medium. This would mean that at physio-
logical pH an optimum for sulfonamide antibacterial acti-
vity is found at a çK value equal to the pH, thus at about 
7. Much data are given in literature in support for this 
hypothesis, whereas other facts are not explainable by it 
(for extended reviews see: M , 55, 60). 
Recently, Miller et al. (38) showed for two homologous 
1 1 
series, N -phenylsulfonamides and N -pyridilsulfonamides, 
that the inhibitory activities of these compounds, measured 
in a cell-free system, were linearly related to their anti-
bacterial activities. Further, it was shown that the inhi-
bitory activity increased linearly with the increase in 
acidity of the compounds. Prom these results. Miller et al. 
concluded that the parabolic relation between pK and 
sulfonamide antibacterial activity is best explained by 
the Breuckner and Cowles theory. However, the pX -range 
a 
of the sulfonamides used by Miller et al. was limited. The 
pK of the most acidic sulfonamide used, N -(2-Br-i4-NOp-
kO 
-phenyl)-sulfonamide, 5·70, is near the pX -range (pK 6-7) 
a a. 
required for maximal antibacterial activity (10, 12, 16). 
To obtain more definite information on this aspect, inhi­
bition studies on the H.-pteroate synthesizing system of 
E.aoli В were undertaken with a heterogeneous series of 
sulfonamides having -pK values from 2.92 to 10.88, and with 
1 1 a 
some Ν N -dialkylsulfonamides. 
11.1.2 METHODS AND MATERIALS 
11.1.2.1 Methods 
The methods employed to estimate the enzymic formation of 
Hp-pteroate and to determine the Inhibition Index of the 
sulfonamides, have been described in chapter 1.2. 
11.1.2.2 Materials 
Sulfanilamide, sulfapyridine, sulfadiazine, sulfamethazine, 
sulfathiazole, sulfacetamide and sulfaethylthiadiazole were 
of Dutch Pharmacopoeia quality. Sulfabenzamide was purchased 
from К & К Laboratories. Sulfadimethoxine, sulfamethoxazole 
and sulfisoxazole were the gift of Roche. Sulfasomidine and 
sulfamoxole were the gift of Nordmark. Sulfanilyl-3,^-xyl-
amine was the gift of Geigy. Sulfanilylcyanamide was syn­
thesized according to Winnek et al. (67). N -phenyl-, 
N1-ethyl-, ^-methyl-, N1N1-dimethyl-, N:1N1-diethyl-, and 
N-ethyl,N -methyl-sulfonamide were prepared by standard 
methods (44). 
11.1.3 RESULTS 
The Inhibition Indices, found for the mono-substituted sul­
fonamides, are listed in Table II.1. For some of these 
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!\j Table II. 1 
Inhibition Index (I.I.)ι pK and antibacterial activities (MIC) of some 
N -substituted sulfonamides 
"-О 
S02NHR 
No. 
1 
2 
3 
i) 
5 
6 
7 
8 
9 
Compound 
N -ethylsulfani: 
N -methylsulfan: 
Sulfanilamide 
N -phenylsulfan: 
Sulfapyridine 
Sulfasomidine 
Sulfamethazine 
Sulfathiazole 
Sulfamoxole 
Lamide 
Hamide 
Llamide 
с 2н 5 
СНз 
Η 
о 
η 
R 
ff* 
с
Ъ
СНз 
и 
СНз 
СНз 
І.І. 
28 
21 
10 
1.90 
0.67 
0.45 
0.51 
0.3^+0.02 
0.27 
І.І.(х)а) 
о.оч 
o.oii 
0.04 
0.18 
0.18 
0.36 
0.42 
0.30 
0.25 
Ρ*α 
10.88c) 
10.77d) 
10.43d) 
8.97f) 
8.i(3d) 
7.4 e ) 
7.34^ 
7.12d> 
7.0 8) 
MIC
b
> 
128 e ) 
16^ 
ц
е) 
2e) 
2.) 
2e) 
3.5h) 
10 
11 
12 
13 
14 
15 
16 
17 
18 
Sulfadiazine 
Suifadirnetboxine 
Sulfamethoxazole 
SuifaethyIthiadiazole 
Sulfacetamide 
Suifanily1-3,4-xylamide 
Sulfisoxazole 
Sulfabenzamide 
SulfanilyIcyanamide 
О 
№с2н5 
еснз 
.H<Ä 
CN 
0.78 
0.27 
0.25 
0.43 
3.5 
0.55 
0.46 
0.95 
5-2 
0.76 
0.27 
0.25 
0.43 
3.5 
0.55 
0.46 
0.95 
5.2 
6.48d) 
5.9 e ) 
5.7 e ) 
5.45e) 
5.3Bd> 
4.95e) 
4.9 e ) 
4.57d) 
2.92 d ) 
l e ) 
l e ) 
l e ) 
2e) 
2e) 
це) 
2e) 
5.6 
a) I.I.(x) means Inhibition Index corrected fer the fraction of the molecules 
ionized at pH = 8, χ = K
a
/((H+) + K
a
). b) Minimum Inhibition Concentration in 
umole/liter for E.coli. c) Determined by Potentiometrie titration of 0,1 mmole 
of the sodium salt with 0.01 N HCl. d) According to Bell and Roblin (10). e) 
According to Seydel et al. C59J. f) According to Seydel (56). g) Determined 
according to the procedure described by Bell and Roblin (10). h) According to 
Seydel and Wempe (58)· H According to Seydel and Wempe (51)· 
sulfonamides. Table II.1 also gives the antibacterial acti­
vities (Minimum Inhibition Concentration) for E.coli, as 
obtained from literature. 
A plot of log (I.I.) and of log MIC veraua pX is shown in 
a 
Fig. II.2. The theoretical curves according to Bell and 
MIC 
100: 
01-4 
Fig. II.2: The relationehip between 
sulfonamide activity and pK
a
, plotted 
on a aemilogarithmio acale. 
в — # Inhibition Index, о — o MIC 
Csee Table II.1), - - - theoretical 
curve according to Bell and Roblin, 
theoretical curve according to 
Breuckner and Coulee. 
UK 
Roblin (10) and Breuckner (12) and Cowles (16) are also 
given. With the exception of sulfadiazine (compound 10) 
and sulfacetamide (compound 14), the logarithm of the 
Inhibition Index showed a parabolic relation to pK , with 
an optimum between pX 6 and 7· 
To investigate the importance of ionization of the sulfon­
amides for the interaction with the PABA binding site, 
H2-pteroate synthesis in the presence of sulfathiazole 
(pX = 7-12) was estimated at different pH values. This 
revealed that the extent of inhibition of H2-pteroate syn­
thesis increases with the concentration of ionized molecules 
(Table II.2). For instance, at pH = 7-0 (42? ionization) 
5 AiM of sulfathiazole (РАЗА 21.9 MM) inhibited the enzyme 
reaction to about ЪЪ%, whereas at pH = 8.0 (88? ionization) 
43? inhibition occurred. A twofold increase of the sulfa­
thiazole concentration at the same extent of ionization, 
however, gave rise to a greater enhancement of the inhibi­
tion (e.g., at pH 8.0 and PABA 21.9 -uM; 4 лМ and 8 ліМ of 
sulfathiazole caused 34? and 50? inhibition, respectively. 
(see Fig. 1.8)). 
If only the ionized form of the sulfonamides is responsible 
for the activity (Breuckner and Cowles), then the Inhibition 
Index, corrected for the ionized fraction, should be in­
dependent of the dissociation constant. However, as can be 
seen from these corrected values (Table II. 1) and from 
Fig. II.3, a complex relation, showing a maximum and a 
minimum between pK and I.I.(x), was found. Since it is 
not likely, regarding the variety in the nature of R, that 
1 
the N -substituent of any sulfonamide directly participates 
in the interaction with the PABA-receptor (10, 43), the 
relation as shown in Fig. II. 3, can not be explained by, 
for instance, sterical requirements for R. Hence, either 
a complex relation exists between the activity of the 
45 
Table II.2 
Relation between the extent of ionization of sulfathiazole 
and inhibition of H^-pteroate synthesis. 
pH a' % Ionized ' Hp-pteroate formed0' % Inhibition 
control sulfathiazole 
5 MM 
7.0 
7-5 
8.0 
8.5 
9.0 
42 
70 
88 
96 
99 
1.23 
2.74 
2.86 
2.25 
1.76 
0.82 
1.71 
1.63 
1.30 
0.93 
33.4 
37.6 
43.0 
4 2 . 3 
47.2 
a) pH of the enzyme reaction medium (PABA is 21.9 juM) 
b) The fraction of sulfathiazole ionized; χ = К
а
/((Н+) + K
a
). 
o) Expreseed in nmolee per mg of protein per hour. 
sulfonamides and their dissociation constant, or the 
assumption that only the ionized molecules are responsible 
for the activity, is not correct. 
To see whether unionized sulfonamide molecules also inter­
fere with the active site of the enzyme H,-pteroate syn-
1 1 . . 
thetase, some Ν N -dialkyl substituted sulfonamides were 
examined for their inhibitory activity. As is seen from 
the data given in Table II.3» Ν N -dialkyl-sulfonamides 
(compounds 19-21) inhibited Hp-pteroate synthesis. Now, 
if it is assumed that the ionized as well as the unionized 
form of the mono-substituted sulfonamides interfere with 
l i 1 1 
t h e PABA-receptor, t h e n N N - d i m e t h y l - and N - e t h y l , N -
-methyl-sulfonamide (compounds 19 and 20, respectively) 
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-10: 
0 l ; 
• 
• \ 
\ 
1
 1 
• 
\ 
\ 
\ 
A * 
10 6.0 Θ0 Ю0 
pKa 
Fig. II. 3'· Semilogarithmio plot of 
I.I., corrected for the ionized frac­
tion χ, vs pK
a
. The ionized fraction 
χ - K/((H+) + К ) . 
are even more potent inhibitors than their mono-substituted 
parent compounds (compounds 2 and 1, respectively). 
II.1.1 DISCUSSION 
Since no permeability factors are involved in cell-free 
H2-pteroate synthesis, the theory of Breuckner and Cowles 
implies, for cell-free activities, maximal activity for the 
sulfonamides which are completely ionized at the test con­
ditions (pH Θ.0). 
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Table II 3 
1 1 Inhibition Index of Ν N -dialkyl-sulfonamides 
no. Compound I.I. 
19 N1N1-dimethylsulfonamide 14 
20 N1-ethyl,N -methyl-sulfonamide 20 
21 N1N1-diethylsulfonamide 35 
The Bell and poblin theory, on the other hand, predicts a 
parabolic relation between activity and pK , since the 
electrondensity of the sulfonyl group, -SO.,-, will only be 
optimal at a particular electron-attracting power of sub­
stituent Ft. As is seen froir Fig. II.2, with the exception 
of sulfadiazine and sulfacetamide, the Inhibition Indices 
of the sulfonamdes tested show a parabolic relation to 
pK . The inhibition of Hp-pteroate synthesis by sulfa-
thiazole at different pH values showed, that the inhibi­
tory activity increases with the degree of ionization of 
the inhibitor (Table II.2). However, the enhancement of 
the inhibitory activity as a result of increasing ionization 
is less than would be expected if only the ionized mole­
cules interfere with the active site of the enzyme. Obvious­
ly, the molecular form is also active. This can be deduced 
from the plot of the logarithm of I.I., corrected for the 
ionized fraction, в рК^ (Fig. II.3), and from the inhibi­
tion experim« 
(Table I] .3). 
1 1 iments performed with Ν N -dialkyl-sulfonamides 
1 1 1 
The high inhibitory activity of Ν N -dimethyl- and of N -
1 1 
-ethyl,N -methyl-sulfonamide compared with N -methyl- and 
ι 
N -ethyl-sulfonamide, respectively, may be explained m 
H8 
terms of the Bell and Roblin theory. Since N -methyl- and 
N -ethyl-sulfonamide are too weak an acid, it has to be 
assumed that the molecular forms are responsible for the 
observed inhibitory activity. The introduction of a second 
electron-repelling substituent on the amide-nitrogen will 
enhance the electronegativity of the -SO.- group, and hence, 
increases the affinity of the compound for the enzyme. As 
can be seen from Table II. 3, the same consideration does 
not hold for Ν N -diethyl-sulfonamide. Apparently other 
factors, possible steric hindrance, may be involved here. 
The experimental findings presented, disprove the statement 
that only the ionized form of the sulfonamides is responsible 
for bacteriostatic activity as postulated by Breuckner and 
Cowles. Moreover, a) the relation between the dissociation 
constant, i.e., the inductive effect of substituent R, and 
the Inhibition Index, and b) the higher inhibitory activi-
1 1 ty of the Ν N -dialkyl-sulfonamides with respect to their 
mono-substituted parent compounds, are explainable by the 
Bell and Roblin theory. However, as already stated in II.1.1, 
it remains questionable whether the electronic distribution 
of the -S0_- group is responsible for the observed relation, 
since no relation between any physico-chemical parameter of 
the -SO-- group and antibacterial activity has been observed 
(18, 59)· On the other hand, some relation between the phy­
sico-chemical properties of the aromatic amino group of 
the sulfonamides and their antibacterial activity has been 
shown by Seydel (55, 59) and by Yonezawa (69). 
If the electrondensity of the aromatic amino group, as 
emphasized by these authors, is the main factor affecting 
activity, then, obviously, an electrondensity on the amino 
group should exist which is optimal for the drug-enzyme 
interaction. This would imply, — regarding the parabolic 
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relationship between the activity of the sulfonamides and 
the inductive effect of substituent R — , the existence of 
a non-linear relation between the inductive effect of R and 
the basicity of the aromatic amino group. Yoshioka (70), 
however, showed a linear decrease of the basicity of the 
amino group with increasing acidity of the sulfonamides, 
indicating that the electronic distribution of the aromatic 
amino group is affected directly, via hyperconjugation, by 
the inductive effect of R. These findings refute a non-
-linear relation between the characteristics of R and those 
of the amino group, as reasoned above. Hence, the parabolic 
dependence of the activity on the dissociation constant of 
the sulfonamides is not related to the physico-chemical 
properties of the aromatic amino group. 
Foernzler and Martin (18), from quantum chemical calculation, 
showed that the antibacterial activity increased with in-
creasing charge on the amide nitrogen. If this latter phy-
sico-chemical property determines the affinity for the en-
zyme, then a similar relation between structure and activity 
as predicted by Bell and Roblin would be expected, since 
the charge on the amide nitrogen will be determined by the 
electron-attracting power of the N -substituent R. 
For whole-cell sulfonamide activity, cell penetration, as 
shown by Fujita and Hansch (19a) and by Miller et al. (38), 
is an important factor. 
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II.2 NUCLEAR-SUBSTITUTED PABA-DERI VAT IVES 
II. 2.1 INTRODUCTION 
Mono substitution in the benzene ring of PABA results in 
compounds which are inactive, sulfonamide-like (PADA-ant-
agonists), PABA-substitutes (agonists) or dualistic (PABA-
-antagonist and -agonist simultaneously) in their mode of 
action on microorganisms (2, 3, 32, 37, 61, 68). The 
different types of action may be based on various mecha-
nisms . 
The PABA-antagonists may, in analogy with the sulfonamides, 
compete with PABA for the active site on the enzyme H»-
-pteroate synthetase. In addition, the PABA-derivatives 
may be converted by the synthetase to a folic acid analog, 
which in its turn may interfere with the coenzymic function 
of THF. 
As far as PABA-deficient microorganisms are involved, the 
PABA-derivatives possibly interfere with the uptake of 
PABA by these microorganisms, for instance, by competition 
with a transport system for PABA. The observation that the 
accumulation of sulfonamide in cells of E.ooli decreased 
in the presence of PABA (^2), might be an indication for 
the presence of a transport system for PABA with which 
PABA-antagonists interfere. 
The agonistic property of PABA-derivatives may be due to 
a metabolic conversion of these compounds by the microor-
ganism to PABA. This possibility, however, seems less 
likely since no metabolic processes are known which, for 
instance, dehalogenate a halogen-substituted benzene with-
out replacing the original substituent by another, e.g., 
oxygen (S'J, 66). More reasonable is the hypothesis that 
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the PABA-substitutes are incorporated by the enzyme Hp-
-pteroate synthetase into a functional pteroate analog. 
For a number of PABA-derivatives it is reported that, 
after incubation of a PABA-deficient strain of E.coli with 
these compounds, the culture medium contained growth 
supporting properties for the folic acid requiring 
Streptococcus faecalis. Folic acid antagonists could ant­
agonize this growth in a surmountable way (4). Further it 
has been shown that various synthetical folic acid analogs, 
substituted in the PABA-moiety, can serve as substitute 
for folic acid in bacteria, e.g.. Streptococcus faecalis 
(15, 30, 53)· The extent to which a PABA-substitute can 
replace PABA is determined by its affinity and intrinsic 
activity (turnover-rate) (2, 3) for the enzyme and by 
the bioactivity of the resulting folic acid analog. 
The dualism in action is explainable with the bio-physi­
cal parameters affinity and intrinsic activity (2, 3). In 
enzymology, intrinsic activity can be translated in turn­
over-rate of the substrate on the converting enzyme. Apart 
from the possibly diverging bioactivity of the ultimate 
product (i.e., folic acid analog), the presence of a PABA-
-substitute having a lower turnover-rate along with PABA, 
reduces, in comparison with PABA being the only substrate, 
the rate of the formation of folate-active product. This 
expresses itself as if the PABA-substitute is a truly com­
petitive antagonist of PABA. This is even more so if the 
bioactivity of the particular folic acid analog is lower 
than that of folic acid. 
The underlying chapter reports the inhibitory activity of 
various nuclear-substituted PABA-derivatives for the cell-
-free Hp-pteroate synthesis in E.coli В and E.coli 273. An 
attempt is made to correlate quantitatively the observed 
inhibitory activities of some of these compounds to their 
structure. 
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II. 2. 2 METHODS AND MATERIALS 
II. 2.2.1 Methods 
The measurement of the enzymic H.-pteroate formation and 
the estimation of the Inhibition Index of the PABA-ant-
agonists were performed as described in 1.2.3.1 and 1.2.^., 
respectively. 
The estimation of the folate activity for Streptooocoue 
faecalie (ATCC 80^3) was performed as described in 1.2.1.1. 
The multiple regression analysis and their statistical 
evaluation were computed with a Bull General Electric 
Time-Sharing Service program. 
II.2.2.2 Materials 
The PABA-derivatives were either supplied by Prof. Dr. 
E.J. Ariens (Head of the Pharmacological Department of 
the University of Nijmegen, The Netherlands), or they 
were synthesized according to known procedures (6l). 
The compounds were carefully purified by crystalliza­
tion in order to remove a possible contamination with 
PABA. The purity of the compounds was checked by melting 
point measurement and thin-layer chromatography. 
II.2.3 RESULTS AND DISCUSSION 
II.2.3.1 Inhibition of H2-pteroate synthesis 
The various PABA-derivatives tested for their inhibitory 
activity for Hp-pteroate synthesis in E.coli В and E.ooli 
273, are listed in Table II. Ί. 2-CH,-PABA, which is a tru­
ly competitive antagonist of PABA for E.coli (3)> showed 
to compete with PABA for the active site on the enzyme 
Hp-pteroate synthetase (Fig. II.4). Its K. value, obtained 
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Table II.И 
Inhibition Index of ring-substituted PABA-derivatives for 
Hp-pteroate synthesis in E.coli В and E.coli 273 
b) 
no. 
1 
2 
3 
1 
5 
6 
7 
8 
9 
10 
11 
12 
13 
11 
15 
16 
17 
18 
19 
Compound a J 
2-NH 2-PABA 
3-NH 2-PABA 
2-OH-PABA 
3-OH-PABA 
2-F-PABA 
2-CI-PABA 
3-C1-PABA 
2-Br-PABA 
3-Br-PABA 
2-CH--PABA 
3-CH -PABA 
2-N0 2-PABA 
3-N0 2-PABA 
2-CH 0-PABA 
2-C 2H 50-PABA 
3,5-(Br) 2-PABA 
2,6-(CH
: 5) 2-PABA 
2-amino-5-oarboxy-
pyridine 
2-amino-5-sulfon-
amidopyridine 
Inl-
E.coli 
8 
10 
20 + 
8 
10 
64 
230 
130 + 
410 
200 + 
470 
200 
360 
110 
700 
800 
600 
libi 
: в 
1. 
8 
13 
.ti( 
.3 ι 
(n= 
(П' 
эп Ine 
in=4) 
= 4) 
= 5) 
ïex ' 
E.coli 
273 
12 
22 
8 
55 
200 
130 
460 
220 
200 
900 
in vivo 
affinity 
relative to 
PABAC> 
80 
200 
500 
1000 
1000 
1000 
a) arabic numbers refer to the position of the eubetituent in 
the PABA molecule in relation to the carboxyl group, e.g., 
2-X-PABA = 4-атіпо-г-Х-Ьепзоіс acid. 
b) Inhibition Index-values are the mean of two determinations 
in duplicate. Each determination ыаа performed at different 
PABA concentrations. 
c) according to Ariëns and Simonis (3) 
d) no detectable inhibition of H.-pteroate synthesis took place. 
с 
ν 
20 
I S 
1.0 
^ ^ ' 1 1 1 1 1 1 i 
2 4 6 
4-dmino-2-iTielhyJ-benioicacjd (mM) 
Fig. II.Ί: The епгутга formation of Н9-
-pteroate in the ргевепее of 2-СН
г
-РАВА 
(Dixon plot). РАБА uM: 28 о — о, 21 
л
—
Δ
, 14 •ν—ν. (υ = nmole ¡¡¡-pteroate/ 
h/mg protein). 
from the curves in Fig. II.4, is 5.1 x 10 M. Also the 
other compounds competed with PABA for the active site. 
This was deduced from the fact that the Inhibition Index, 
estimated at at least two different PABA concentrations, 
appeared to be almost constant (variation + 15%). 
Whereas the mono ring-substituted derivatives of PABA 
exhibited affinity for the PABA-receptor, the di-substitu-
ted compounds (3,5-dibromo- and 2,6-dimethyl-PABA) did not 
inhibit the Hp-pteroate synthesis up to the concentration 
tested (15 mM). The pyridine analog of PABA, 2-amino-5-
-carboxy-pyridine, which is able to antagonize the anti-
bacterial activity of sulfonamides (3, 36), showed weak 
inhibitory properties. The importance of the benzenoid 
structure for the interaction with the PABA-receptor is 
also shown by the decreased affinity for the enzyme of the 
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pyridine analog of sulfanilamide (I.I. = 600, compound 19)> 
in comparison with sulfanilamide (I.I. = 10, Table II.l). 
The enzyme system from both strains of E.coli exhibited 
the same characteristics concerning the affinity for the 
PABA-derivatives (Table II.4). This may indicate that the 
antibacterial properties of these compounds for E.coli 273 
are due to competition with PABA for the enzyme Hp-pteroate 
synthetase, rather than competition with PABA for a transport 
system. Additional support for this conclusion can be ob-
tained from the affinities of some of these compounds relative 
to PABA, as estimated by growth experiments with E.coli 273 
(3). These in vivo affinities are about proportional to the 
particular Inhibition Indices (Table II.4). 
II.2.3.2 Folate activity for Streptococcus faecalie 
To investigate whether in the cell-free system of E.coli 
273 pteroate analogs were formed from the PABA-derivatives, 
reaction mixtures in which the compounds served as sub-
strate, were tested for their growth-promoting property 
for Streptococcus faecalie. This revealed that only the 
reaction mixtures incubated with 2-halogen-PABA and 2-
-amino-5-carboxy-pyridine exert growth activity for the 
organism (Table II.5)· Synthetically prepared folic acid 
analogs modified in the benzene ring of PABA, i.e., derived 
from 2-F-PABA, 2-C1-PABA (30) and 2-amino-5-carboxy-pyri-
dine (53), are substitutes for folic acid in S.faecalie 
(30, 53). These facts point out that the observed growth-
-supporting property of the reaction mixtures incubated 
with compound 5, 6, 8 and 18 (Table 11.4), is probably due 
to pteroate analogs formed from these compounds. The fact 
that no growth activity was found to be present in the 
reaction mixtures incubated with the other compounds, may 
indicate that: a) no pteroate analogs were formed; b) the 
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Table II.Ч 
Substrate 
РАВА 
2-F-PABA 
2-Cl-PABA 
2-Br-PABA 
2-amino-5-•carboxy-
- p y r i d ine 
cono. 
(mM)a) 
0.02 
0.5 
2 
3 
15 
Growth response, expressed as relative folate equivalents, 
for Streptococcus faecalis of the cell-free system of 
E.coli 273 in which PABA-derivatives served as substrate 
relative 
folate equivalents 
100 
83 
40 
5 
a) concentration of the corresponding compound, used 
in the enzyme reaction 
pteroate analogs formed from these compounds are unfit for 
use for S.faecalis; с) the pteroate analogs are folic acid 
antagonists. 
If pteroate analogs which are modified in the PABA moiety, 
act as inhibitors of bacterial cell-processes, their site 
of action is not likely to be the dihydrofolate reductase 
system. For a compound to be a competitive inhibitor of 
the reductase, an enhanced electrondensity in the pyrimi— 
dine ring of the pteridine nucleus is required. This can 
be achieved, for instance, by substituting the 4-hydroxy 
group of the pteridine by an amino group. Variation in 
the p.aminobenzoyl-glutamic acid moiety of folic acid 
hardly influences the affinity of the compound for the 
enzyme, nor the turnover of the compound (28, 39, 41, 48). 
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In case of the pteroate analog of 2-CH--PABA, the latter 
consideration may be valid, for preincubation of E.ooli 273 
with 2-CH -PABA resulted in retardation of growth-recovery 
of the organism (5> 6). A possible explanation for this 
might be that an a-functional folic acid analog is formed 
which exerts antibacterial activity (lethal synthesis) (7). 
Synthetic 2'-CH,-folic acid showed slight inhibitory acti­
vity for S.faeealia (30). 
To determine a possible "anti-folate" activity, samples of 
the reaction mixtures were added to a series of assay tubes 
containing folic acid assay medium and, respectively, 0.1; 
0.2; 0.4; 0.7; 1 and 2 ng folic acid per ml. The tubes were 
inoculated with S.faecalis (1 drop of an 8 h culture) and 
incubated at 37° for about 20 h. 
No growth-inhibitory activity was found to be present in 
the reaction mixtures. This would mean that, either no 
pteroate analogs were formed or, the analogs are inert to 
S. faecal is, for instance, because S. faecalis is not able 
to transform the particular pteroates to the corresponding 
folic acid analogs. In case of ρ.aminosalicylic acid 
(2-OH-PABA), its incorporation into H?-pteroate by the 
cell-free system, could be shown clearly by the use of 
1
'
)C-labeled 2-OH-PABA (chapter III). 
II.2.3.3 Relation between structure and activity 
From the Inhibition Indices listed in Table 11.4, it can 
be seen that the introduction of a substituent in the ben­
zene ring of PABA decreases the affinity for the enzyme 
Hp-pteroate synthetase. Comparison of PABA-derivatives 
substituted in the ortho or meta position (in relation 
to the carboxyl group), shows that meta substitution, in 
general, is less tolerated than ortho substitution. Fur­
ther, it is seen that increase in bulk of the substituent, 
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e.g.. Cl to Br, or decrease in electronegativity, e.g., Br 
to CH, decreases the affinity. 
It is shown by a number of workers in the field of structure-
-activity relationships, that free energy related substituent 
constants (e.g., Hammett σ-value, Taft steric parameter Ε , 
8 
Hansch partition coefficient π) in an extrathermodynamic 
approach, may correlate quantitatively molecular structure 
and biological activity in a linear way (22, 2^, 26, 27, 
35). 
Equation 1 represents the equilibrium between an inhibitor 
I and an enzyme E: 
1) E + I ±^.EI K . - E • I 
i EI 
The change in free energy, as the result of the interaction 
of the enzyme with the inhibitor, as a first approximate, 
can be factored as follows (26, 39): 
2
> Mil - Klect. + ^steric + ^L/H 
In equation 2, ÛF°, . represents that portion of the free 
energy change that can be attributed to electronic effects, 
ΔΡ". - represents the steric requirement of the reactant 
on the free energy change, and А?°. represents the contri­
bution to the free energy as resulted from hydrophobic 
bonding. 
The effect of substituenta on the change in free energy of 
a reference molecule then can be represented by equation 3: 
3 )
 &
x
àF0EI - 6 X < l e c t . + asterie + δ χ Δ ί Ί / * 
Since δ AF° = ffr.lnU / Я 0 ) . and the I n h i b i t i o n Index ( I . I . ) 
i s r e l a t e d to K./K (chapter 1.2.4), equation 4 can be 
ъ τη 
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derived for the relation between the Inhibition Index and 
physico-chemical parameters: 
4) log(I.I.) = ρσ + b E + cv + d 
X 8 
In equation 4, (I.I.) is the Inhibition Index of the 
derivative substituted with χ; a, E and π are the free 
8 
energy related constants of substituent χ which reflect 
the substituent effects as described in equation 3. The 
coefficients p, b, a and d are estimated by the methods 
of least squares. Terms which are not statistically sig­
nificant can be eliminated by stepwise regression analysis. 
This approach has been applied to evaluate a quantitative 
relation between the structure and the inhibitory acti­
vity of some PABA-derivatives. Orifco-substituted PABA-
-derivatives were only used in the regression analyses, 
since for these compounds sufficient independent numbers 
of observations were available. 
It should be recognized, however, that the linear model 
used to describe the relationship, is an approximation 
which, although empirically confirmed in a number of 
cases (22, 24, 26, 27, 35), needs not to hold in the case 
at issue. Therefore, the interpretation of the results 
should be considered in this light. 
Results: 
The PABA molecule possesses two functional centres (COOH 
and NHp), which both are essential for its biological action 
(43)· For the ortho substituent, therefore, two sets of σ 
and π constants can be chosen depending on the reaction 
centre which is considered. It was thought that, by corre­
lating on the one side σ and IT values and on the other 
o o 
side σ and π values to the biological activity, it should 
m m " " * 
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be possible to discriminate between both the reaction 
centres (COOH and NH , respectively) as far as their im­
portance for the interaction with the PABA-receptor is 
concerned. Namely, if the carboxyl group is considered to 
be the important centre for the enzyme-substrate inter­
action, σ and π constants should give a high correla-
5
 о о о о 
tion. If, in contrary, the amino group is the main reac­
tion centre, σ„ and π constants should show the best fit. 
* m m 
As far as the steric parameter concerns, Charten showed 
the Taft E -parameter to be related to the van der Waals 
radius and independent of electronic effects (13> 33). 
Hence, the steric effect, expressed as E , of the ortho 
substituent in PABA-derivatives affects only the spatial 
demands of the active site of the enzyme, and thus is in­
dependent of which reaction centre is under consideration. 
The E value of hydrogen (= 1.2^) was subtracted from the 
3 
E values of the substituents, in order to have hydrogen & 
as reference (£ (H) = 0.0) (23). 
The respective substituent constants for compounds 5, 6, 
8, 10, 12 and Ik (Table II.U) are listed in Table II.6. 
2-NH2-PABA and 2-CH-PABA (compounds 1 and 3, Table II.1) 
were left out from the regression analysis. The reason 
for this will be discussed later. 
Table II.7 summarizes the results of the statistical 
evaluation of the different linear combinations between 
logd.I.) and the respective physico-chemical parameters 
in case the carboxyl group of PABA was taken as the reac­
tion centre (equations 5-11). The results obtained in case 
the amino group was considered to be the reaction centre, 
are given in Table II.8 (equations 12-16). 
An F-ratio test of the regression analysis of the correla­
tion between log(I.I.) and Ε , showed the relation to be 
8 
significant (equation 6, Table II.7). This relation, 
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Table II.7 
Equations describing a linear relation between log (I.I.) of the compounds listed 
in Table II.6 and the various free energy related substituent constants. 
a) General equation: log (I.I.) = ρσ + ЬЕ + οπ + d (η = 13 ') 
b ) с 
eq. parameter coefficients 
5 
6 
7 
θ 
9 
10 
11 
σ 
О 
+ 
+ 
+ 
+ 
E 
в 
+ 
+ 
+ 
+ 
π 
О 
+ 
+ 
+ 
+ 
F - v a l u e c ) 
F I M I = 0 . 3 5 
F L U = 5 . 2 5 
F i , i i = 0 . 7 9 
F 2 , i o = 2 2 . 1 
F 2 , i o = 0 . 5 7 
F 2 , i o = 2 . 8 3 
Fy,, = 16.И 
NS 
X 
NS 
« X * 
NS 
NS 
XXX 
Ρ 
- 0 . 2 0 NS 
- 1 . 0 1 XXX 
- 0 . 2 1 NS 
- 1 . 0 0 XX* 
b 
- 0 . 4 0 X 
- 0 . 8 2 xxx 
- 0 . 3 9 ( x ) 
- 0 . 8 0 xxx 
a 
0 . 2 1 
0 . 2 2 
0 . 1 0 
0 . 1 1 
NS 
NS 
NS 
NS 
d 
2.0 
1.6 
1.9 
1.2 
2 . 0 
1 . 5 
1 . 1 
8
d > 
0 . 3 7 
0 . 3 1 
0 . 3 7 
0 . 1 7 
0 . 3 8 
0 . 3 2 
0 . 1 7 
2 e J 
r 
0 . 0 3 
0 . 3 2 
0 . 0 7 
0 . 8 2 
0 . 1 0 
0 . 3 6 
0 . 8 5 
a) η is total number of independent determinations of the Inhibition Index at the 
same PABA concentration performed with the 6 compounda (Table II.6). 
b) The respective parameters used, alone or in combination, to describe the correla­
tion. 
c) Used symbols: NSt p>0.10 , not significant 
(*), 0.0S <pi0.10 j indication of significancy 
X, 0.01 <p(0.05 , significant 
XX, O.OOKp^O.Ol , id. 
XXX, p^O.001, id. 
d) s, standard deviation 
e) r*, index of determination 
Table II.8 
Equations describing a linear relation between log (I.I.) of the compounds listed 
in Table II.6 and the various free energy related substituent constants. 
a) General equation: log (I.I.) = ρσ + ЪЕ + σπ + d (η = 13 ) 
eq. parameter coefficients 
12 
13 
14 
15 
16 
σ E ir 
m e m 
+ 
+ 
+ + 
+ + 
+ + + 
F - v a l u e 
F , , i i = 1 .20 NS 
F i , , ! - 0 . 0 0 NS 
Fi,io = 9 . 2 1 * * 
Р г . ю = 0 . 7 0 NS 
F3,9 = 5 , θ 0 * 
Ρ 
-0.1)7 NS 
- 0 . 9 2 * 
- 0 . 5 8 NS 
- 0 . 9 9 * 
b 
- 0 . 5 7 * * 
- 0 . 5 6 » t 
o 
0 . 0 1 NS 
0 . 1 6 NS 
0 . 1 1 NS 
d 
2 . 1 
2 . 0 
1.6 
2 . 1 
1.6 
β 
0 . 3 6 
0 . 3 8 
0.21) 
0 . 3 7 
0 . 2 5 
r
2 
0 . 1 0 
0 . 0 0 
0 . 6 5 
0 . 1 2 
0 . 6 6 
a) For the meaning of the eymbola eee Table II.7. 
СГу 
Table I I . 6 
Physico-chemical parameters of the subs t i tuents in ortho-
-subs t i tu ted PABA-derivatives 
н 2 г д ( Г 1 ) С О О Н 
α
 a> α b ) π c ) π d> E e ) 
o m o m a 
5 
6 
8 
10 
12 
14 
F 
Cl 
Br 
СИ, 
N0 2 
осн3 
0.24 
0.20 
0.21 
-0.17 
0.80 
-0.39 
0.3Ί 
0.37 
0.35 
-0.07 
0.71 
0.11 
0.0Ί 
0.59 
0.75 
0.68 
-0.23 
-0.33d) 
0.40 
0.98 
1.10 
0.50 
0.47 
0.03 
-0.46 
-0.97 
-1.16 
-1.24 
-2.52 
-0.55 
α) aooording to Taft (62); Ъ) according to Jaffé 
(31); с) according to Kutter and Mansch (34); d) 
according to Fujita et al. (19); e) Ε
β
 values ob­
tained by subtracting 1.24 from the Eg values given by Kutter and Hansch (34). 
however, accounts only for 32% (r2 = 0.32) of the variance. 
A single-parameter-equation used for correlating log(I.I.) 
to the other substituent constants (equations 5, 7, 12 and 
13), turned out to be an invalid description of the rela­
tionship. 
The linear combination of the electronic parameter (σ) and 
the steric parameter U
s
) , on the other hand, yielded a 
much improved correlation (equations 8 and 14). Equations 
8a and 14a represent equations 8 and 14, in which, in 
addition, the 95% confidence intervals are given: 
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8a) log(I.I.) = -1.01(+0.11)а - 0.82(+0.28)F + 1.2(+0.32) * 
— o — β ρ
 — 
s = 0.17 г = 0.82 
lia) logd.I.) = -0.92(+0.68)σ - 0.57(+0.32)ff + 1.б(+0.3б) * 
— m — s •" 
s = 0.21 г = 0.65 
Both equations show a negative sign for the coefficient of σ 
and for the coefficient of E . The negative relation to E 
indicates that the PABA-receptor, at the ortho position of 
the carboxyl group, does not tolerate bulky groups. This, 
probably, is even more so for the meta position, since the 
meta-substituted PABA-derivatives showed a weaker affinity 
for the enzyme than the orifco-substituted PABA-derivatives 
(Table II.1). The negative sign of ρ in both equations 
may indicate, that a decrease of the electrondensity in 
the benzene ring enhances the affinity for the PABA-recep­
tor. For the correlation represented by equation 8a, which 
is based upon the carboxyl group as being the primary reac­
tion centre, this would mean, that enhancement of the aci­
dity of the carboxyl group (i.e., the increase of the 
electrondensity at the carboxyl group by ionization) in­
creases the extent of the interaction with the receptor. 
It is of interest to note the observed value for ρ (equa­
tion 8a). This value is about 1, which, in fact, is the 
p-value for the dissociation of substituted benzoic acids 
(31)· This might indicate that the interaction of the com­
pounds with the enzyme is dependent on the ionization of 
the carboxyl group. These considerations, in fact, seem 
to confirm the hypothesis that a negative charge, located 
at the carboxyl site of the PABA molecule, is most favour­
able for the interaction (10, 12, 16) (see also chapters 
The absolute values of the coefficiente as well as of the 
intervals are only meaningful if the linear description of 
the relationship is a correct supposition. 
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II.1 and ІІ.3)· li" the same reasoning is set up for the 
aromatic amino group (equation l'ía), the negative ρ then 
suggests, that the affinity for the enzyme increases if 
the basicity of the amino group decreases. This would be 
in agreement with the observation that the antibacterial 
activity of a series of N -phenylsulfonamides increased 
linearly with decreasing basicity of the aromatic amino 
group (55) . 
It is questionable, however, whether the interpretation of 
equation l^a, concerning the aromatic amino group, can be 
justified. First; the σ values used are probably invalid 
in this situation, since the electronic effects of the 
substituents will be influenced — in an unknown way — 
by the adjacent carboxyl group. This may also explain the 
ρ 
rather poor correlation of equation l^ a (i· = 0.65). Second­
ly, the negative correlation to σ may rather refer to the 
carboxyl group than to the amino group. 
The addition of the hydrophobic constant, π, to both re­
gression analyses, resulted in a slight improvement of the 
correlations (equations 11 and 16). T-statistics, however, 
revealed π not to be significant. This would indicate that 
the compounds do not bind hydrophobically to the enzyme. 
For sulfonamides, it was also shown that hydrophobic inter­
actions with the enzyme H_-pteroate synthetase were not in­
volved (38). 
Table II.9 summarizes the observed and calculated log (I.I.) 
values of the compounds used in the regression analyses. In 
The observed increase in antibacterial activity of the 
Я -phenylsulfonamides is probably not due to the decrease 
in basicity of the aromatic amino group, but rather to the 
increase of the acidic strength of the particular sulfon­
amides (see chapters II.1 and II.3). 
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Table II.9 
Log(I.I.) values of ort/io-substituted PABA-derivatives 
observed, and calculated according to equations 8, 14 or 16. 
R 
F 
Cl 
Br 
сн3 
N0 2 
OCH, 
NH2 
OH 
obs. 
1.00 
1.80, 
2.14, 
2.19 
2.30, 
2.24, 
2.30 
2.00, 
0.90 
1.30 
1.74 
2.03, 
2.36, 
2.27 
2.06 
log(I. 
cale. 
(eq.8) 
1.31 
1.76 
1.91 
2.36 
2.43 
2.02 
.1.) 
cale. 
(eq.l4) 
1.55 
1.81 
1.94 
2.37 
2.38 
1.81 
2.09 
2.02 
cale. 
(eq. 16) 
1.52 
1.84 
I.98 
2.37 
2.32 
1.76 
I.90 
1.66 
addition, the predicted log(I.I.) values of 2-NH -PABA and 
2-OH-PABA, calculated by applying equations 14 and 16, are 
given. This shows that, notably, the activity of 2-NH--PABA 
is poorly predicted. Involvement of both compounds in the 
regression analysis (linear combinations of σ , π and E ) 
m m e 
deteriorated strongly the correlations. Other phenomena, 
such as hydrogen bonding between the substituent and the 
carboxyl group, apparently are involved with both com­
pounds. Intramolecular hydrogen bonding enhances the 
acidity of the benzene carboxyl group (20) and, since equa­
tion 8 suggests that increase of the acidity of the carboxyl 
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group will increase the affinity for the enzyme, the con-
siderations mentioned above might well explain the relative-
ly high affinities of 2-NH2-PABA and 2-OH-PABA. 
II.3 PABA-DERIVATIVES SUBSTITUTED IN THE CARBOXYL GROUP 
II.3.1 INTRODUCTION 
Statistical evaluation of the data on structure and Inhibi­
tion Index of nuclear-substituted PABA-derivatives (chapter 
II.2.3-3) resulted in a positive relation between the acidi­
ty of the carboxyl group and the affinity for the enzyme 
Hp-pteroate synthetase. A clear-cut relation between the 
chemical reactivity of the aromatic amino group and the 
inhibitory activity of the PABA-derivatives was not found. 
Nevertheless, the primary aromatic amino group is of con­
siderable importance for the biological activity of PA3A-
-agonists as well as -antagonists (Ί3, 55). The chemical 
reactivity of this group in relation to the biological 
activity has been emphasized. Schiff-bases of some thera­
peutic sulfonamides are more stable to hydrolysis than 
the corresponding Schiff-base of PABA (59)· Seydel et al. 
(59) showed a relation between the bond force and/or bond 
angle of the amino group and the bacteriostatic activity 
of different sulfonamides. A linear relation between the 
basicity of the amino group and the bacteriostatic activi-
ty was shown for a series of N -phenylsulfonamides (55)· 
Yonezawa et al. (69) were able to show for two sets of four 
sulfonamides, a linear relation between the antibacterial 
activity and the reactivity (expressed as electrophilic 
superdelocalizability ) of the amino group. 
The basicity of the aromatic amino group of sulfonamides 
decreases linearly with the increase of the acidity of the 
sulfonamide -SO-NHR- group (70). (The deviation of the 
acidity of sulfonamides from that of sulfanilamide (R = H) 
is determined by the inductive effect of R). The antibac­
terial activity of the sulfonamides as well as the affini­
ty of the compounds for the PABA-receptor, however, showed 
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a parabolic relation to the inductive effect of the N -
-substituent (see chapter II.1). If the aromatic amino 
group predominantly determines the activity of PABA-ant-
agonists, a complex relation must exist between the 
physico-chemical properties of this group and the bio­
logical activity. 
To obtain more information on this aspect, PABA-deriva-
tives, either substituted in the amino group or in the 
carboxyl group, have been tested for their inhibitory 
activity for the cell-free H--pteroate synthesizing 
enzyme system. 
II.3.2 MATERIALS AND METHODS 
The compounds studied, were either obtained from commer­
cial sources (compounds: 1-5, 11, 12, li, 15, 17, 24, 25), 
or synthesized according to known procedures. The amides 
of PABA were synthesized from ρ.nitrobenzoylchloride and 
the corresponding amine by the Schotten-Baumann procedure. 
The ρ.nitrobenzamides were reduced to the amino deriva­
tives by catalytical hydrogénation (H./PtOp). Ethyl-p.amino-
benzoyl-acetate (compound 13) was obtained by reduction of 
the corresponding nitro compound (Aldrich) (H-ZPtO. in 
ethylacetate). All compounds derived from PABA were care-
fully purified by recrystallization in order to remove 
possible contamination by the latter. 
pX' values were determined by Potentiometrie titration of 
0.1 mmole of the HCl-salt of the compounds with 0.01 N NaOH. 
The procedures employed to determine the enzyme activi-
ty, the Inhibition Index and folate activity for Strepto-
coccus faecalis (ATCC О^З) have been described in chapter 
1.2. 
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II.3.3 RESULTS AND DISCUSSION 
11.3.3.1 Benzoic acid derivatives 
Preliminary experinents with benzoic acid derivatives 
(benzoic acid, m.aminobenzoic acid, ρ.acetylaminobenzoic 
acic, m.hydroxybonzoic acid, p-η-butylaminobenzoic acid 
and ρ.nitrobenzoic acid), showed that none of these com­
pounds interfered with the cell-free Hp-pteroate synthesis. 
The inability of ρ.nitrobenzoic acid to interact with the 
PABA binding-site, which also л'аз shown for the cell-free 
system of Pneumoaoacus (^ 5j 46), confirms the postulate 
that the PABA-antagonistic property of ρ.nitrobenzoic 
acid in bacteria is not due to the compound itself but to 
a metabolite of ρ.n:trobenzoic acid (З-Ьуагоху-Д-атіпо-
benzoic acid?) (37). ρ.Hydroxybenzoic acid, which was re­
ported to inhibit H.-pteroate synthesis in different 
strains of Pneunococcus (^5), hardly showed inhibitory 
properties for tne enzyme system of Е.аоіъ (about 10% 
inhibition occurred at a ρ.hydroxybenzoic acid - PABA 
ratio of 600). 
The inactivity of these benzoic acid derivatives concerning 
Kp-pteroate synthesis, confirms the importance of the 
primary aromatic amino group in the PABA molecule. 
11.3.3.2 Para-substituted anilines 
Tne innibitory activities, expressed as Inhibition Index, 
of some para-substituted anilines are listed in Table 11.10. 
With the exception of ρ.aninophenylacetic acid (compound 3), 
the compounds do not possess a carboxyl group. Aniline and 
para alkyl-anilines (compounds 1-3) do not interfere with 
the cell-free Hp-pteroate synthesis. Compounds 4 - 1 4 , 
which have a carbonyl group para to the amino group in 
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Table 11.10 
Inhibition Index and pK' of para substituted anilines 
нум 
Compound no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
It 
R 
H 
с н
з 
сн2соон 
COOCH, 
соос2н5 
C0NH 2
a ) 
C0NHCH3
b) 
C0N(CH 3) 2
b ) 
C0NH(CH2)2C6H5
C) 
CONHCgH a ) 
COCH, 
сос 2н 5 
сосн 2соос 2н 5
е ) 
сос 6н 5 
I.I. 
-
-
-
450 
600 
53 
120 
koo 
800 
600 
210 + ll d ) 
180 + 7 d ) 
105 
800 
p*¿ 
3.30 
3.30 
3.A2 
3.15 
3.19 
3.41 
з . з ч 
3.23 
3.26 
з.іч 
a) re/. 5; b} ref. 65; a) ref. 11; d) S.E.M. (n = 4) 
e) ref. 14. 
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common, competed with PABA for its binding site. 
The inhibitory activity of the PABA-esters and -amides (com­
pounds 'J-IO) might be due to PABA, originating from the 
compounds by hydrolysis (see chapter 1.2. Ί.2). However, no 
detectable hydrolysis was observed at the test conditions, 
indicating that the inhibition is due to these compounds. 
From the inhibitory activities of compounds Ί - H , it is 
seen that substitution of the carboxyl-hydroxyl group in 
PABA considerably reduces the affinity for the enzyme. Since 
PABA (ρλ = 4.68) is almost completely ionized at the pH-
-optimum of the enzyme reaction (pK = 8.0-8.5)» it is 
reasonable to assume that PABA in its ionized form inter­
acts with the enzyme. Also for sulfonamides it was shown 
that the ionized form possessed enhanced affinity over 
the molecular form (chapter II.l). From these facts one 
might conclude that the weak inhibitory activity of com­
pounds Η - Ш, is mainly due to the impossibility to create 
a negative centre in this part of the molecule. 
A dependency seems to exist between the polarizability of 
the carbonyl group and the inhibitory activity. This pos­
tulate can be visualized for compounds 11 - 13. Hotchkiss 
and Evans (29), on basis of incubation experiments of 
ρ.aminoacetophenone (compound 11) with sulfa-resistant 
strains of Pneumoaoccus, already postulated that the acetyl 
group in this compound should show a charge distribution 
like the carboxyl group in PABA in order to interact with 
the PABA-receptor. This suggests a polarisation (enolisa-
tion) of the acetyl group. The keto-enol equilibrium will 
be more in favour of the enolic form in case of p.amino-
propiophenone (compound 12), since for this compound the 
enolic structure is stabilized by hyperconjugation with 
the α-methyl group (21). This would mean an enhanced 
affinity of ρ.aminopropiophenone in comparison with 
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ρ.aminoacetophenone, which indeed was shown by the respec­
tive Inhibition Indices (Table II.9). Additional support 
for this assumption was given by the more potent inhibi­
tory activity, compared with compounds 11 and 12, as ob­
served for ethyl-p.aminobenzoyl-acetate (compound 13)· 
This compound will exist mainly in the enolic form, since 
its structure is stabilized by hydrogen-bonding between 
the enolic hydrogen and the ester-carbonyl group, resul­
ting in a stable six-membered ring structure (21). The 
low affinity of ρ.aminobenzophenone (compound 1Ό is 
probably due to the inability of enolisation of the keto 
function, although steric factors may also be involved. 
The affinity of the methyl and ethyl ester of PABA, in 
comparison with the ketones (compounds 11-13), was poor. 
Since spatial demands of the receptor site apparently are 
not involved, — ρ.aminopropiophenone (compound 12), for 
instance, is about 3 tines more effective as inhibitor than 
its geometric equivalent methyl-p.aminobenzoate (compound 
4) — , the lower affinity of the esters has to be ascribed 
to the lesser polarizability of the ester-carbonyl group. 
The carbonyl group of amides, on the contrary, is more 
polarized because of its conjugation with the lone electron-
-pair of the amide-nitrogen. This night explain the rela­
tively high affinity of ρ.aminobenzamide (compound 6) for 
the enzyme H--pteroate synthetase. The decreased affinity 
1 1 
of N -methyl- and N -dimethyl-p.aminobenzamide (compounds 
7,8) was unexpected, since substitution of the amide-hydro­
gens by electron-repelling methyl groups, as was shown for 
N -dialkyl-sulfonamides (chapter II.l), would enhance the 
polarizability of the amide-carbonyl group. Obviously 
other factors, such as steric intolerance, are involved. 
No clear-cut relation between the basicity of the 
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amino groap and the inhibitory activity of these compounds 
could be discerned (Table 11.10). However, it might be that 
the prerequisites for the aromatic amino group are drowned 
in the poor affinity of these compounds. 
И.З-З-З Peptide analogs of PABA 
In contrast to the N -substituted ρ.aminobenzamides shown 
in Table 11.10, ρ.aminobenzoyl-L-glutamic acid (L-PABG) 
(compound 15), which can serve as a biological substrate 
for the enzyme H.-pteroate synthetase resulting in the 
formation of 7,8-dihydrofolic acid (see Pig. 1.1), showed 
a relatively high affinity for the PABA binding site 
(Table 11.11). Its optical isomer, D-PABG (compound 16), 
Table 11.11 
Inhibition Index of some peptide analogs of PABA 
Compound no. R I.I. 
15 (L) NHCH(COOH)CH2CH2COOH 
16 (D) NHCH(C00H)CH2CH2C00H
b 
17 NHCH2C00H 
18 NH(CH2),C00H
c) 
a) re/. eSj Ъ) réf. в; о) réf. 49. 
76 
250 
260 
700 
а) 
а) 
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inhibited Hp-pteroate synthesis to a lesser extent; I.I. 
of L-PABG is 76 (63) and of D-PABG is 260. Obviously, in 
addition to a specific PABA binding-site, a stereo-selec­
tive accessory receptor site seems to exist. To investigate 
the different parts of the glutamic acid molecule (see 
formula) for their contribution to the affinity for the en­
zyme, ρ.aminohippuric acid (PAH) and N-p.aminobenzoyl-γ-
-aminobutyric acid (compounds 17,1Θ) were tested for their 
inhibition of the H.-pteroate synthesis. 
HOOCfCH yCH2CH2COOH 
J 
glycine y-aminobutyric aoid 
1—glutamic acid 1 
This revealed that PAH was about 3 times more active than 
N-p.aminobenzoyl-y-aminobutyric acid (Table 11.11). Further, 
it appeared that the affinities of PAH and D-PABG were of 
the same order of magnitude, indicating that for the latter 
compound the butyric acid moiety does not contribute to 
the affinity. 
As discussed for the esters and amides of PABA (this chap­
ter, II.3-3.2), also for compounds 15 - 18 (Table 11.11) 
I1) the observed inhibition of ( C)Hp-pteroate synthesis 
might be merely the reflection of (enzymic) hydrolysis of 
the p.aminobenzamides to PABA. However, in case of L-PABG 
this consideration does not find any support. Namely Richey 
and Brown (52) showed that only dihydrofolic acid was formed 
from L-PABG in a cell-free system, whereas in case of 
hydrolysis also Hp-pteroate should have been formed. If 
hydrolysis of the amide-bond should occur, it was thought 
that the rate of hydrolysis would not be influenced by 
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esterií'ication of the carboxyl group of, for instance, 
L-PABG and PAH. In any case, esterification should not 
influence the difference in rate of hydrolysis between 
L-PABG and PAK; hence, the found ratio between the Inhibi-
tion Indices of both compounds should also be observed for 
the esterified compounds. However, as is seen from the In-
hibition Indices of the esterified compounds (diethyl ester 
of L-PABG and methyl ester of PAH) listed in Table 11.12, 
esterification reduced the affinity, and both compounds 
showed about equal inhibitory activity. Obviously no 
hydrolysis of the amide function was involved. 
Table 11.12 
Compound no. Compound I.I. 
19 diethylester of L-PA3Ga^ 600 
20 methylester of PAHb^ 550 
a) ref. 64; b) ref. 40. 
The decreased affinities of compounds 19 and 20 suggest 
that a dissociable and/or hydrophilic function (carboxyl 
group) is involved in the interaction of compounds 15 - 18 
with the accessory binding-site. Additional support for 
this consideration was obtained by the observed inhibitory 
activity of the compounds listed in Table 11.13. N-p.amino-
benzoyl-2-aminobenzoic acid and N-p.aminobenzoyl-3-amino-
benzoic acid (compounds 21,22) were about twice as active 
as their common parent compound, N-p.aminobenzoyl-aniline 
(compound 10). Esterification resulted in a decreased 
affinity (compound 23, Table 11.13). 
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Table i ; . 1 3 
Н ^ ( ( y>CONHR 
Compound R I . I . С H N m.p. 0 C 
n o . 
21 -A)) г 5 0 t h : 65-61 4.72 10.93 215-218 
Р ^ Γ: 65-43 5.13 10.76 
соон 
22 / ^ , 250 th: 65-61 і(.72 10-93 255-:-'57 
Г: 65-70 4.68 10.82 
<С00Н 
23 ^ ^ 800 th: 66-90 5-23 10.40 178-180 
f: 67-04 5-24 10.31 
СООСН, 
The РАВА ester, 6-diethylaminoethyl-p.aminobenzoate (procaine) 
also seemed to fit the hypothesis. However, its amide analog, 
procainamide, did hardly inhibit H^-pteroate synthesis 
(Table 11.14). This paradox let us to look for hydrolysis 
of procaine as a possible explanation for its observed 
inhibitory activity. Therefore, procaine was preincubated 
for different periods with the cell-free system before 
Hp-pteroate synthesis was started by the addition of H?-pter 
Table 11.14 
Compound no. compound I.I. 
24 procaine 110 
25 procainamide 1000 
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1 11 
and PABA. This revealed that the inhibition of ( C)H2-
-pteroate synthesis increased with increasing preincubation 
of procaine (Table 11.15), indicating that PABA was generated 
14 
which results in inhibition of the turnover of ( C)PABA. 
Table 11.15 
ΙΊ 
"Inhibition" of ( C)Hp-pteroate synthesis by procaine in 
relation to the preincubation period of procaine with the 
system 
Time of incubation (min) % Inhibition of 
of procaine with the sys- Ho-pteroate synthe-
tem from which H2-pter sis in the second. •, 
and PABA were omitteda). incubation period . 
0 12 
15 23 
30 из 
1)5 56 
a) Reaction mixtures (520 jug protein) were ae 
described in 1.2.3.1. Procaine, 1 ілМ. 
b) Я2-ріег (40 JUM] and PABA (22.3 JUM) were added 
after the first incubation period. The incubation 
was continued for 30 min. 
Regarding the chemical similarity of the amide substi­
tuants of compounds 15 - 20, the reactivity (basicity) of 
the primary aromatic amino group will be about the same 
for these compounds. (pX' of the methyl ester of p.amino-
hippuric acid is 3.39). Hence, the large differences in 
activity of the compounds cannot be accounted for by the 
small differences in basicity of the aromatic amino group. 
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ІІ.З.З·
1! Folate activity for Streptococcus faecalis 
Reaction mixtures, in which compounds 10, 15 - 19, 21 and 
2^, instead of PABA served as substrate for the enzyme 
H.-pteroate synthetase, were investigated for the presence 
of folate-like activity by testing their growth-promoting 
properties for Streptococcue faecalis. From the results, 
presented in Table 11.16, it is seen that besides PABA and 
Table 11.16 
Growth response for Streptococcus faecalis of the cell-free 
system of E.coli in which PABA derivatives served as sub­
strate 
a) Compound Compound cone. relative growth 
no. (mM) equivalents produced 
100 
92 
30 
11 
1.5 
1 
-3-aminobenzoic 
acid 8 7 
21 procaine 1.5 96 
a) Concentration of the substrate, used in the enzyme reac­
tion. 
15 
16 
17 
18 
19 
9 
21 
PABA 
L-PABG 
D-PABG 
PAH 
N-p .aminobenzoyl-
-γ-aminobutyric 
acid 
diethylester of 
L-PABG 
N-p.aminobenzoy1-
-aniline 
N-p.aminobenzoyΙ­
Ο.02 
3 
8 
8 
10 
6 
6 
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L-PABG, also the incubation with D-PABG, PAH, procaine and, 
to a lesser extent, with N-p.aminobenzoyl-3-aminobenzoic 
acid, resulted in the formation of compounds with folic 
acid-like activity. This would mean that, either PABA is 
liberated from the compounds resulting in the formation 
of Hp-pteroate or, from the compounds pteroic acid analogs 
were formed which can serve, either directly or as precur-
sor, as growth factor for S.faecalis. However, as already 
stated in II.3.3.3, the generation of PABA by hydrolysis 
occurred only from procaine, indicating that from the other 
compounds pteroate analogs were formed. (Incubation experi-
ments with isotope-labeled p.aminohippuric acid showed the 
formation of N-7,8-dihydropteroylglycine (chapter III)). 
Since compounds 10, 18 and 19 have very weak affinity for 
the enzyme H.-pteroate synthetase, the formation of pteroic 
acid analogs from these compounds, if this occurs, will be 
very small. 
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II.'I B-p.AMINOBENZOYL-PROPIONIC ACID AND DERIVATIVES 
ΙΙ.Ί.Ι INTRODUCTION 
The results obtained from studying cell-free Hp-pteroate 
synthesis in the presence of various PABA-derivatiV'-s 
(chapter II.3), revealed that a para-aminobenzoyl function 
is required for compounds to interact with the PABA-recep-
tor (sulfanilamide and derivatives are left out of considera­
tion). Further, from the results obtained with peptide 
analogs of PABA it was concluded that a stereo-selective 
accessory receptor site should exist which requires (an) 
acidic function(s) (chapter IT.3.3.3). и/ith M¡ese l'-ctb 
in mind, compounds were designed which should interfc-re 
with the enzymic turnover of PABA, and from which addi-
tional information about the active site on the enzyre 
H2-pteroate synthetase was expected. 
β-ρ.Aminobenzoyl-propionic acid (РАЗУ) (Fig. IÌ.5), geo-
metrically equivalent with ρ.aminohippuric acid, was chosen 
as model compound. 
H2N^jNt;CH2CH2COH H2N^JftCNHCH2COH 
$-p.aminobenzoyI- p.aminohippuria 
-propionic; acid acid 
Fig. II.5 
II.1.2 METHODS AUD MATERIALS 
II.1.2.1 Methods 
The estimation of the cell-free Hj-pteroats synthesis and 
the determination of the Inhibition Index of compounds which 
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interfere with the enzyme reaction, were performed as des­
cribed in chapter 1.2. 
Growth experiments with E.ooli 273 
E.coli 273 was cultivated in a synthetic medium (chapter 
1.2.2.1). The growth of the organism, in the presence or 
absence of potential PABA-antagonists, was followed as a 
function of the PABA concentration. Assay-tubes, containing 
10 ml of the culture medium, were inoculated with one drop 
of an 8 h culture of E.coli 273, grown in the medium 
supplemented with 10 M PABA. The incubation was performed 
at 37 · Growth of the organism was assayed by measuring the 
turbidity (% transmission) with a Coleman Model 9 nephelo-
meter. 
II.1.2.2 Materials 
Compounds 3, Ί and 5 (Table 11.17) were synthesized according 
to known procedures (references: 17, 50 and 50, respectively). 
The synthesis of compounds 1, 2 and 6 - 1 0 are described in 
chapter V.2. 
II.1.3 RESULTS AND DISCUSSION 
11.4.3.1 S-p.Aminobenzoyl-propionic acid 
A Dixon plot of the cell-free Hp-pteroate synthesis in the 
presence of PABP (Fig. II.6) showed that the compound 
competed with PABA for the active site on the enzyme H?-
-pteroate synthetase. Its affinity (X. = 130 ¿iM) is in 
the same order of magnitude as the affinity of L-PABG 
(K. = 170 MM (63)), and about 5 times higher than of its 
geometric analog ρ.aminohippuric acid (the Inhibition In­
dices are 55 and 260 (63), respectively). The reason for 
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ß-ßammobenzoyl propionic acid (mM) 
Fig. II.6: H2-pteroate synthesis ίκ 
the presence of 8-p.aninobenzoyl-
-propionic acid (Dixon plot), ν is 
the amount of H2-pteroate formed in 
dpm (1000 dpm - 89.2 χ 10~^2 moles) 
per· h per 570 ug of protein. PABA 
juM; о — о 28. в, 0 — · 14. 4j 
а — Δ 7.2. 
the difference in affinity between PABP and ρ.aminohippuric 
acid is not clear. Enolisation of the koto-function of PA3P 
may be involved, for polarisation (enolisation) of the 
carbonyl group was shown to enhance the affinity for the 
enzyme (chapter II.3.3.2). Esterification of PABP, like 
esterification of L-PABG and of ρ.aminohippuric acid 
(chapter II.3.З.З), resulted in a decrease of the affini­
ty (Table ILI?). The affinity of the ethyl ester of PABP 
(compound 2) is about 3 times weaker than the affinity of 
ρ.aminopropiophenone (the Inhibition Indices are ^60 and 
I80 (63), respectively). Obviously, compared with 
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Table 11.17 
Inhibition Index of (З-р.aminobenzoyl-propionic acid (РАВР) 
and derivatives thereof 
no. Compound I.I. 
1 PABP 55 + 2 (n = 5) 
2 ethyl, B-p .ammobenzoyl-propionate 460 
3 B-p•acetylaminobenzoyl-propionic acid 
4 ß-benzoyl-propionic acid 
5 y-p .aminophenyl-butync acid 
ρ.aminopropiophenone, the additional ethyl-carboxylate group 
is unfavourable for tne interaction vith the PABA-reoeptor. 
Modification of PABP, either by acetylation of the 
aromatic aruro group (compound 3), or substitution of this 
latter group by hydrogen (compound k), or by reduction of 
the xeto-function (compound 5), nullified the affinity for 
the enzyme (Table 11.17). The inactivity of compounds 3 - 5 
underlines the importance of a primary aromatic amino group 
and of a carbonyl group para to the amino group, for the 
interaction with the PABA-receptor. 
II.4.3.2 a-Phenyl-B-p.aminobenzoyl-propionic acid 
Hydrophobic bond formation, in general, results in appreciable 
gain in affinity (1). Therefore, derivati\es of PABP in which 
a phenyl group a to the carboxyl group was introduced, were 
investigated for their inhibitory activity for the cell-free 
rip-pteroate synthesis. In Pig. II.7, a Dixon plot of the 
Hp-pteroate synthesis in the presence of (dl)-a-pheryl-
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04 08 12 16 го 24 
α-phenyl-ß-p.aminobenzoyl-propionic acid (mM ) 
Fig. II. 7' Η 2-pteroate syr.thesis in 
the presence of a-phenyl-fS-p. атгпо-
benzoyl-propionie acid (Dixon plot). 
PABA uM: о — о 26.8, · — # 14.4. 
-ß-p.aminobenzoyl-propionic acid (compound 6) is shown 
(K. = 150 AIM). At first sight, it seems that the introduc-
tion of a phenyl group hardly influences the affinity of 
PABP. By substitution at the α-carbon atom, however, an 
asymmetric centre is introduced. Since it was shown that 
the assumed accessory receptor site is stereo-selective, 
it might well be that only one of the optical isomers of 
compound 6 is responsible for the observed affinity. The 
dextero-rotary isomer, (ci)-a-phenyl-fî-p . aminobenzoyl-pro-
pionic acid, showed a 6 times weaker affinity for the en-
zyme than the racemate. In Table 11.18, the Inhibition 
Indices of the racemate (compound 6) and of the respective 
optical isomers are given. The Inhibition Index of the 
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Tablo l i . 1 3 
Innibi t ion Index of {dl)-, (d)- and (H-a-phenyl-ß-p.amino-
benzoyl-propionic acid 
H 2 N<Q>0 CCH2CH 
COOH 
no . CoTipound I . I . 
raoemate 7 4 + 3 (n = Ό 
d 480 
l 4 0 a ) 
a) The Irhib¡.tion Index of the 
l-isomer was oaloulated by apply-
ing equation 1. 
levo-rotary isomer was calculated from the values of the 
racemate and the d-iso-ner by eauation 1 (47): 
Kd . Kl 
1) KV -- 2. г 
ь 
ι. 
г ζττ
1 
In equation 1, Kr represents the equilibrium constant of the 
enzyme-racetiate interaction and К. (K ) the equilibrium con­
stants of the isomers. 
Since the enzyne H^-pteroate synthetase is a soluble protein 
with a small molecular weight (51)j it is unlikely to assume 
that m the cell-free system used, transport phenomena which 
could discriminate between stereo-isomers (25), are responsible 
for the observed stereo-selectivity. 
Although the leuo-isoirer showed increased inhibitory activity 
in comparison with PABF, the enhancement in affinity for the 
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enzyme is only small. Obviously, lipophilic interactions 
with the additional receptor site, like lipophilic inter­
actions with the PABA-receptor (chapter II.2.3.3), are not 
significant for the binding to the enzyme. 
Substituants in the α-benzene ring of a-phenyl-ß-p.amino-
benzoyl-propionic acid decreased the affinity for the enzyme. 
In Table 11.19» the Inhibition Indices of four derivatives 
of compound 6 are given. As can be seen from these values, 
substitution on the para-position of the benzene ring de-
creased the affinity to a greater extent than substitution 
on the meta-position. 
Table 11.19 
Inhibition Index of a-phenyl-S-p.aminobenzoyl-propionic acid 
H2N<Q>(ÌCH2CH<Q^R 
cooH 
no. R I.I. 
7 para bromo 195 
θ meta bromo 150 
9 para methoxy 175 
10 meta methoxy 110 
II.1.3.3 Activity to E.coli 273 
To investigate whether the compounds possess antibacterial 
activity, the growth of the PABA-requiring strain E.coli 273 
was followed with PABA in the presence of PABP or a-phenyl-
ß-p.aminobenzoyl-propionic acid. No inhibition of growth 
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was observed. On the contrary, when PABA was present in 
submaximal concentration, maximal growth occurred in the 
presence of PABP ( Ю - 3 M). In the presence of the a-phenyl-
-derivative of PABP (10 M) enhanced growth was observed 
(Pig. II.8). This may indicate that the microorganism is 
able to convert the compounds to PABA. 
10 10~7 i c r 6 (M) 
p.ammobenzoic acid 
Fig. II.8: Growth of E.ooli 273 after 
22 h incubation at 37° as a function 
of the PABA concentration. · — · 
control, о — о in the presence of 
ß-p.атіпоЪепгоуl-propionic acid (1 mM). 
Δ — Δ in the presence of a-phenyl-ë-
-p.aminobenzoyl-propionic acid (1 mM). 
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Cell-free systems containing PABP or compound 6, and from 
which PABA was omitted, did not show growth-promoting pro-
perties for the folic acid-requiring microorganism Strepto-
eoccue faecalia, indicating, that in case pteroate analogs 
were formed from these compounds, these pteroate analogs 
cannot function as substitutes for folic acid in S. faeoalis. 
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Ill THE ENZYMIC FORMATION OF 2'"OH,H -PTEROATE AND 
H -PTEROYLGLYCINE 
III.l INTRODUCTION 
In chapter ΙΙ.2.3·2, it was shown that the incubation of 
the Hp-pteroate synthesizing systera in the presence of 
some PABA-derivatives (i.e., 2-F-PABA, 2-C1-PABA, 2-Br-
-PABA and 2-a!nino-5-carbojcy-pyridine) gave rise to the 
fornation of compounds which exerted growth-promoting 
activity for Streptococcus faecalis. In chapter ΙΙ.3·3·4, 
it was snown that the incubation of the cell-free system 
witn L-PABG, D-PABG, ρ.aminohippuric acid (PAH), or 
N-p.aminobenzoyl-3-aminobenzoic acid, ended up in folate 
activity for S.faecalis. 
These facts may inaicate that compounds, others than PABA, 
which interact with the PABA-receptor, also become coupled 
to the pteridine substrate by the enzyme Hp-pteroate synthe­
tase. Support for this assumption is given in literature: 
Wacker et al. {h) isolated from a culture of Enterococaus 
ЗЬег which was incubated with " C-labeled ρ.aminosalicylic 
acid (2-OH-PABA = PAS), a radioactive compound which, on 
basis of its chromatographic behaviour, was identified as 
a folate-like substance but, in contrast to folic acid, 
did not support growth of S.faecalis. Also for non-PABA-
-like compounds, such as sulfonamides, indication is ob­
tained for their coupling to the pteridine substrate (1). 
In this chapter clear-cut evidence is presented for the 
enzymic formation of 2'-OH,Hp-pteroate and Hp-pteroylglycine 
(Fig. III.l) from ρ.aminosalicylic acid and ρ.aminohippuric 
acid, respectively. 
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Fig. III.l. 
ι 
Η Η 
2 '-0Η3Η 2-pteroate Η„-ρ teroylglyci ne 
III.2 METHODS AND MATERIALS 
111.2.1 Assay for the enzymic 2'-OHjK.-pteroate formation 
To estimate the formation of 2'-ΟΗ,Ηρ-pteroate, the same ex­
perimental procedure was followed as for the assay of the 
H^-pteroate synthesis (chapter 1.2). To the incubation mix-
1 ti tures (see chapter 1.2.3.1) (7- C)PAS was added instead 
of PABA. The enzyme reaction was stopped by the addition 
of a citric acid - phosphate buffer, pH = 2.4 (this pH was 
found to be optimal for the extraction of PAS with ether). 
The extraction of the reaction mixtures and the preparation 
of the counting vials were performed as described in chap­
ter 1.2.1.2. 
111.2.2 Assay for the enzymic H.-pteroylglycine formation 
Since PAH is only sparingly soluble in water-immiscible 
organic solvents, separation of the substrate and product 
of the enzyme reaction could not be performed by extraction 
procedure. Therefore, product and substrate were separated 
by means of paper chromatography. 
To the incubation mixtures (chapter 1.2.3.1) (2-3H)PAH was 
added instead of PABA. The enzyme reaction was stopped by 
addition of 0.5 ml ethanol. Of the final mixture, 50 дді was 
spotted on 3 cm broad strips of Whatman paper no. 1, and 
chromatographed at room temperature by the descending 
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technique. The eluting solvent was 0.1 M potassium phos­
phate buffer, pH 7-0. After development of the chronatogram, 
— the front was advanced about 20 to 25 cm — , the paper 
strip was cut into pieces of 1 cm and these were put into 
counting vials containing 10 ml Packard Insta-gel. 
III.2.3 Materials 
i^  (7- C)PAS (spec. act. 7 8 mCx/mmole) was obtained from 
CEA, France. (2- H)PAH (spec. act. 22.4 mCi/mmole) was ob­
tained from the Radiochemical Centre, England. 
II1.3 RESULTS AND DISCUSSION 
III.3.1 Incubation hith PAS 
In Fig. III.2, the radioactivity which was not extractable 
from the reaction mixtures with ether, is plotted versus 
time of incubation. This radioactivity increased linearly 
with ture and the rate remained unchanged for at least 2 h. 
Tre radioactivity found in the water layer remained at a 
2 + 
constant level if essential cofactors (ATP or Mg ) for 
the enzyme system леге omitted from the reaction mixtures. 
Neither increase of ether-insoluble radioactivity was ob­
lìi 
served rfhen ( C)PAS was incubated with the pyrophosphoryl 
ester of Hp-pter in the presence of denaturated enzyme. 
These findings point to an enzyne-med^ated reaction. The 
nature of the radioactive substances in the water and in 
the ether layer was examined by paper chromatography, using 
0.1 M potassium phosphate buffer (pH = 7.0) as the eluting 
solvent (2). This revealed that the radioactive compound 
present m the ether layer migrated with Rf O.S'Jj which is 
identical witi the R, of PAS. The radioactivity, present 
in the water layer remained at the start of the chromatogram. 
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extracts of E.ooli В 
Plot of the radioacti 
maining in the water· 
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phase after ether 
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he amount of pro­
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уте reaction, 
action mixture 
action mixture 
on mixture with-
114 χ JO - 3 2 moles). 
The R . of Hp-pteroate in this chromatographic system is 
0.0 (2, 3). 
A Dixon plot of the enzymic turnover of PAS in the presence 
of PABA, showed that the enzymic reaction was competitively 
inhibited by the latter {K. 2 /UM) (Fig. 111.3). The X of 
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I (nmole per mgoF protein per hour)' 
Fig. 111.3· υίχοη plot of the turnover of PAS in 
the presence of PABA. » » PAS 72 мМ, о о 
PAS 54 XiM. 
PAS, calculated from these curves, is ^8 ліМ. The aTfinity 
of PAS, relative to PAEA in that way is 24. This value is 
in good agreement with the relative affinity of PAS, ex­
pressed as Inhibition Index, as obtained from inhibition 
studies of Kp-pteroate synthesis (chapter 11.2.3·!)· These 
results strongly argue for the formation of г'-ОН.Нр-
-pteroate from PAS catalysed by the enzyme t" -pteroate 
synthetase. 
III.3-2 Incubation with PAH 
A paper chromatogram of the cell-free system which was in­
cubated with Η-labeled PAH, showed the presence of two 
radioactive areas (Fig. ІІІ.Ч). One area represented PAH 
(R. = О.76), the other one remained at the start of the 
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Fig. III.4: Paper chromatogram of the cell-free 
system of E.coli В (580 мд of protein per reac­
tion mixture), incubated for 1 hour with (2-^H) 
PAH (880 мМ). Experimental conditions as des­
cribed in section 111.2.2. PAH, Дƒ = 0.76. 
chromatogram. The Д. of glycine in this chromatographic sys­
tem is 0.8?. The radioactivity remaining at the start was 
not found when the pteridine substrate, ATP or Mg was 
omitted from the reaction mixture. Microbiological assay 
revealed that the area around the origin of the chromato­
gram only showed growth activity for Streptococcus faecalis. 
Fig. III.5 clearly shows the linear decrease of ( H)PAH 
concomitant with a linear increase of the radioactivity 
at the start, during time of incubation. These findings 
taken together, point to an enzymic conversion of PAH 
under conditions of H.-pteroate synthesis. A Dixon plot 
of the enzymic turnover of PAH in the presence of a com­
petitive inhibitor of the enzyme H2-pteroate synthetase 
(2-CH,-PABA (chapter II.2.3.1)), is depicted in Fig. III.6. 
^ -4 
The K. value of 2-CH,-PABA thus obtained is 5 x 10 M. 
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Fig. III.5: The enzymia conversion of 
PAH during different incubation periods. 
Protein content per reaction mixture, 
580 мд. PAH 880 ¿iM. · — · Radioactivity 
(cpm) remaining at the start of the 
chromatogram, 7 — 7 PAH, Лƒ = 0.76, 
Δ — л total radioactivity. 
This value is nearly the same as the K. found for the en-
zymic H?-pteroate synthesis (X. = 5·Ί χ 10 M (chapter 
ІІ.2.3.І)). The ratio between the affinities of 2-CH3-PABA 
and PAH {K of PAH, calculated from the curves in Fig. 
III.6, is 7.3 x 10 M) is 0.68. This value agrees well 
with the ratio between the relative affinities of the com­
pounds for the enzyme Hp-pteroate synthetase. The relative 
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CM 0.6 OB 1.0 
Z-CHj-PABA (mM) 
Fig. III.6: Enzym-ia conversion of (2- И) 
РАН in the présence of Σ-Οϋ^-ΡΑΒΑ (Dixon 
plot), ν = radioactivity (cpm) remaining 
at the start of the chromatogram per 
reaction mixture (580 ug of protein) 
after 1 h incubation at 37°. · — · PAH 
880 мМ, О — о PAH 440 MM. 
affinities of 2-CH,-PABA and of PAH are 200 and 260, res­
pectively (3). Their ratio is 0.77· 
From these findings it has to be concluded that the enzyme 
Hp-pteroate synthetase is involved in the enzymic conversion 
of PAH, and as a result, H2-pteroylglycine is the product 
of the enzyme reaction. 
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IV DIHYDROFOLATE REDUCTASE INHIBITORS AND THE CELL-FREE 
H2-PTEROATE SYNTHESIS 
IV.1 IKTRODUCTION 
Inhibitors of dihydrofolate reductase constitute an other 
class of compounds which interfere with the biosynthesis of 
tetrahydrofolic acid (THF) (see Fig. 1.1). Their mode of ac­
tion is a blocking of the enzymic reduction of dihydrofolic 
acid (DHF), or folic acid, to THF by way of interference with 
the active site of the reductase. In contrast to the sulfon­
amides whose effect is bacteriostatic, dihydrofolate reduc­
tase inhibitors, at higher concentrations, exert cytostatic 
activity. This possibly is due to a total blockade of the 
formation of THF, whereas in case of sulfonamides THF can be 
formed from the DHF-pool inside the bacterial cell (DHF is 
formed in turn from THF via thymidilate synthetase), which 
allows the cell to maintain a basal metabolism (6,12). 
Dihydrofolate reductase is common to all living organisms. 
This implies that inhibitors thereof not only affect the THF 
supply of the parasite but also that of the host, and hence 
cause toxicological side-effects (1,2,^,5,6,10,11). The ex­
tensive work of Hitchings and ooaorkers in the field of folic 
acid antagonism, has led to the development of dihydrofolate 
reductase inhibitors with selective affinity for the reductase 
originating from different sources (3,8). For instance, the 
affinity of trimethoprim for the enzyme from Proteus vulgaris 
is 10 times higher than that for the enzyme from rat liver. 
From growth-kinetic studies with E.coli in the presence of 
trimethoprim, Seydel et αΖ.(12) proposed that trimethoprim, 
separate from its known inhibition of dihydrofolate reductase, 
might have an additional site of action. 
The enzymes H.-pteridine-CH-OH pyrophosphokinase and H.-pter-
oate synthetase, which are involved in the biosynthesis of 
ΙΟΊ 
H2-pteroate from H.-pter and PABA (see Fig. 1.1), have with 
the enzyme dihydrofolate reductase a binding site for a 
2-amino-1i-hydroxy-7,8-dihydropteridine moiety in common. 
Therefore, an additional mode of action possibly can be cre­
dited to the dihydrofolate reductase inhibitors, namely bloc­
king Hp-pteroate synthesis. 
IV.2 METHODS AND MATERIALS 
IV.2.1 Methods 
The methods employed to estimate the cell-free conversion of 
С PABA to Hp-pteroate have been described in chapter 1.2. 
IV.2.2 Materials 
Aminopterin and methotrexate were the gift of Lederle. Tri­
methoprim and pyrimethamine were the gift of Wellcome. 6-Hy-
droxy-2,1) ,5-triaminopyrimidine was purchased from Aldrich. 
5-Acetylamino-2-amino-') ,6-dihydroxypyrimidine was prepared 
according to Hitchings et al. (7)· 
IV.3 RESULTS 
Incubation experiments showed that, up to the concentrations 
tested (H -pter to пП, PABA 21.3 «M), the dihydrofolate reduc­
tase inhibitors aminopterin (5 mM), methotrexate (5 mM), tri­
methoprim (1) mM) and pyrimethamine (6 mM) did not inhibit the 
cell-free Hp-pteroate synthesis from Hp-pter and PABA. Pyri-
midine analogs, containing a hydroxy1 group, i.e., 6-hydroxy-
-2,4,5-triaminopyrimidine (5 mM) and 5-acetylamino-2-amino-
-4,6-dihydroxypyrimidine (8 mM) showed slight inhibitory ac­
tivity (lOiS and 16% inhibition, respectively). 
IV.4 DISCUSSION 
The experiments with the cell-frre H_-pteroate synthesizing 
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system in the presence of dihydrofolate reductase inhibitors 
indicate, that the active sites for the pteridine moiety on 
the enzymes Hp-pteridine-CH-OH pyrophosphokinase and Hp-pter-
oate synthetase differ from that of dihydrofolate reductase 
in that neither of the enzymes involved in Hp-pteroate syn-
thesis, are blocked by the íj'í-diaminopyrimidines and/or the 
2,1l-diaminopteridines studied. 6-Hydroxy-2,4,5-triaminopyri-
midine, bearing a carboxyl group at the correct position, 
showed only slight inhibition of Hp-pteroate synthesis. These 
facts might indicate, that the pyrimidine part of the pteridine 
plays not that important role for the interaction with the 
enzymes which are involved in the Hp-pteroate synthesis, as 
is the case with dihydrofolate reductase. On the other hand, 
2-amino-4-hydroxy-6-carboxy-7,B-dihydropteridine strongly 
inhibits the pyrophosphorylation of H?-pter (9). This might 
indicate, that the-substituted dihydropyrazine moiety of the 
pteridine substrate is the structural element primarely in-
volved in the interaction with tne pteridine binding site on 
the enzyme Hp-pteridine-CHpOH pyrophosphokinase. 
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V SYNTHESIS 
V.l PTERIDINES 
V.l.l INTRODUCTION 
The actual pteridine substrate for the enzyme H.-pteroate 
synthetase is the pyrophosphoryl ester of S-amino-'t-hydroxy-
-6-hydroxymethyl-7)8-dihydropteridine (Fig. V.l, compound 
III. See also Pig. 1.1). This compound is obtained by re­
duction of the pyrophosphoryl ester of S-amino-il-hydroxy-
-6-hydroxymethylpteridine, which can be prepared by heating 
compound I (Fig. V.l) with pyrophosphoric acid or poly-
phosphoric acid (15,16 ,20). The latter synthesis, however, 
is not straightforward but results in mixtures of phospho-
rylated pteridine which can only be separated by extensive 
chromatographical procedures (14,15,16) . 
OH 
I . R 
I I . R 
F i g . V . l 
= сн2он 
= CHO 
он 0 0 
HjN^^N^^N· 
Η 
III 
The difficult accessibility of the pteridine substrate for 
H?-pteroate synthetase can be bypassed, — as has been the 
While preparing the manuscript, Visaontini and Furuta des­
cribed a simplified method to separate the mixture of phos-
phorylated pteridines by using a Dowex 1x8 (CI ) column (20). 
IO8 
case in the studies described in the foregoing chapters — , 
by using an enzyme system which also contains the enzyme 
Hp-pteridine-CH_OH pyrophosphorokinase. This enzyme con­
verts 2-amino-i)-hydroxy-6-hydroxymethyl-7,8-dihydropteri-
dine (H.-pter) to III. ATP serves as the pyrophosphoryl 
donor (see Fig. 1.1). 
6-Hydroxymethylpteridine (I), the key compound in the pre­
paration of the pteridine substrates necessary for studying 
H?-pteroate synthesis, was first synthesized by Waller et 
al. (22). The compound was obtained from 2-amino-4-hydroxy-
-6-formylpteridine (compound II, Fig. V.l) by the Cannizzaro 
disproportionation reaction. The 6-formylpteridine was pre­
pared from folic acid by treating the latter with sulfurous 
acid and iodine, respectively. This procedure to prepare I 
is most widely used. However, the yield of б-formylpteridi­
ne (II), the first step in this synthetical procedure, after 
necessary purification is low (5-30?). 
The pteridine-derivatives, either I or II, can also be ob­
tained by condensation reactions starting from 6-hydroxy-
-2,'4,5-triaminopyrimidine (2 ,3>8,17,19). Most of these methods, 
however, have the disadvantage that, either mixtures of pte-
ridines (6 and 7 substituted) are obtained which are difficult 
to separate, or several synthetic steps are involved (2,3,8, 
17,19)· The method to prepare I, free of its 7-isomer, as 
described by Baugh and Shaw (3)) in our efforts always re­
sulted in mixtures of pteridines. 
In this chapter, an alternative method to prepare 6-formyl-
pteridine (II), in good yield, from folic acid, and its re­
duction to 6-hydroxymethylpteridine (I) by sodium borohydri-
de, is described. 
It was shown by Waller et al. (22) and by Tschesche (18), that 
the 6-methylene group of 6-alkyl substituted pteridines is 
susceptible to bromination in acidic medium. Angier and 
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Curran (1), and Cosulich et al. (5) showed that folic acid, 
when treated with equimolar or di-equimolar amounts oí' bro-
mine gives З'-bromo- or 3'5'-dibromofolic acid respectively. 
With these facts in mind, it was thought that treatment of 
folic adid with excess bromine would not only result in 
bromination of the benzene ring but also the 6-methylene 
group. The resulting product might then undergo cleavage 
to form 6-formylpteridine (II) and ^-атіпо-ЗjS-dibromoben-
zoyl-L-glutamic acid, possibly via hydrolysis of a Schiff-
-base intermediate. 
Heating a solution of folic acid in 'to? hydrogen bromide 
containing excess bromine, resulted in gas (CO,) evolution, 
and the formation of a bright yellow precipitate. The pre­
cipitate consisted of two compounds, one soluble in organic 
solvents, the other insoluble. Analysis of the pale yellow 
insoluble compound (UV, NMR), revealed that it represents 
6-formylpteridine (II) (50-60? yield). Comparison of the 
spectral data of II thus obtained, with the spectral data 
of II, obtained by the method of Viscontini and Bieri (19), 
showed the compound to be of equal purity. The soluble com­
pound appeared to be 2,4,6-tribromoaniline (m.p. and mass 
spectrum), and was obtained in almost quantitative yield. 
Obviously, the benzoylglutamic acid moiety has been, either 
before or after cleavage of the folic acid molecule, dis­
integrated, to give finally tribromoaniline. The formation 
of 2,4,6-tribromoaniline is also observed when 4-amino-3,5-
-dibromobenzamide is treated with excess bromine (Ό. 
V.l.2 EXPERIMENTAL 
V.l.2.1 2-Amino-1i-hydroxy-6-formylpteridine II 
Folic acid (2.2 g, 5 mmoles) (Merck, Darmstadt) was added 
to a stirred solution of k g (25 mmoles) bromine in 10 ml 
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Ц0% hydrogen bromide. When all the folic acid had dissolved, 
the solution was heated to 100 for 2 hours with continuous 
stirring. The resulting precipitate was collected by filtra­
tion, washed thoroughly with water and hot acetone, respec­
tively. The yield of 6-formylpteridine after drying in 
vacuo at 50 was 520 mg. Concentration of the filtrate to 
about 3 ml, treatment with activated charcoal and adjusting 
to pH 3 with NaHCO , gave additional 40 mg of the aldehyde. 
Total yield: 58?. 
From the acetone extract, 1.26 g 2,4,6-tribromoaniline was 
obtained. Its melting point, after recrystallisation from 
50? ethanol, was 119 - 120°. 
Spectral data of II: UV in 0.1 N NaOH: λ 256 nm (E1* 760), 
shoulder 277 nm (E1* 520), λ 367 nm (E1* 413), λ . 230 
ι« ιч
 max
 тгп 
(E1* 350), λ . 308 nm (E1'4 200); in 0.1 N HCl; λ 319 nm 
1« тгп ι«
 max 
(E1* 440), *
min_247 nm (E
1
* 200). NMR (Varían А-бО, F ССООН); 
C(9)H: S, 9-84 ррт, 1 Pr; С(7)Н: S, 9.10 ррт 1 Pr. 
Anal. Cale, for С H N 0 2: С, 43-98; Η, 2.63; Ν, 36.64. 
Found: С, 43.00; Η, 2.78; Ν, 36.23· 
V.l.2.2 2-Amino-4-hydroxy-6-hydroxymethylpteridine I 
Reduction of II to I was performed with sodium borohydride 
as suggested by Angier(3)· 
6-Formylpteridine (II), 50 mg, was dissolved in 10 ml 0.1 
N NaOH. NaBHj. (150 mg) was gradually added during 30 min 
with continuous stirring· After 2 hours stirring at room 
temperature, the reaction mixture was acidified with cone. 
HCl to pH 3. The precipitated pteridine was collected by 
centrifugation, washed with water, ethanol and ether, and 
dried in vacuo at 50 . The yield was 32 mg (63%). 
Spectral data: UV in 0.1 N NaOH; λ 254 nm (E1^ 1300), 
- a max 
X
mr7r 366 nm (E
1
* 365), λ . 230 (E** 400), λ . 300 nm 
max ïïi%n ш п 
(El* 85). 
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These data are in accordance with the data given by Waller 
(22) and Baugh and Shaw (5). 
V.l.2.3 2-Αιηΐηο-Ί-hydroxy-6-hydroxymethy1-7,8-dihydropteri-
dine (H2-pter) 
The reduction of 6-hydroxymethylpteridine to its 7,8-di-
hydro-derivative (H.-pter) is achieved with sodium dithio-
nite. The commonly used procedure of Futterman (i.e., in the 
presence of ascorbate) (10) or of Priedkin (i.e., in the pre­
sence of 2-mercaptoethanol) (9), appeared to be unsatis­
factory in that the reduction not always proceeded for 10055 
(checked by UV spectrophotometry). 
To reduce 7,8-disubstituted pteridines to their 7,8-dihydro 
form, Pfleiderer and Zondler refluxed the compounds in 
alkaline medium with sodium dithionite (13)· This modifica­
tion was employed to prepare Hp-pter from I. 
' Ϊ ; 
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F i g . V .2 : ί/Κ s p e c t r a in 0.1 N HCl. 
H„-pter3 6-hydroxymethylpte 
ridine (I). 
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Procedure : 
6-Hydroxymethylpteridine (I), 50 mg, was dissolved in 15 ml 
0.1 N NaOH and heated to about 100°. Sodium dithionite, 400 
mg, dissolved in 2 ml water, was gradually added to the 
stirred solution. After 20 min stirring at 100 , the pH of 
the reaction mixture meanwhile had fallen to 6.3, the reac-
tion mixture was chilled on ice and 3 drops of 2-mercapto-
ethanol were added. Concentrated HCl was added to bring the 
pH to 2.8. The precipitated H.-pter was centrifuged, washed 
3 times with 0.1 M 2-mercaptoethanol and lyophilized. Yield, 
36 mg {60%). 
The UV spectrum of H -pter (in 0.1 N HCl), together with the 
spectrum of I, is shown in Fig. V.2. 
Since Hp-pter is susceptible to air oxidation, the content 
-01NMCI ¿OINHCI 
c
 m»* (·* 2S3nm) / L min(=»230nm ) 
1 0 J 
100% 
Mj-pter 100% e-CHjOH pter 
Fig. V.3: Plot of the ratio between the 
absorption maximum in the regio of 250 
nm and the absorption minimum in the 
regio of 230 nm (see Fig. V.2) versus 
the "contamination" of ¡¡¿-pter by 6-
-hydroxymethylpteridine {6-CH2OH pter -
I). For 100% I, the absorbanae at 240 nm 
(see Fig. V.2) is ohosen. Its "ratio" is 
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of H -pter in the product was determined by ÜV spectro-
photometry before each enzyme experiment. The ratio between 
the maximum at 253 nm and the minimum at 230 nm was taken 
as a measure of the Hp-pter content. This ratio is about 
1.8 for the pure compound (Fig. V.2). 
In Fig. V.3, the change of the ratio of the absorption 
maximum in the regio of 250 nm and the absorption minimum 
in the regio of 230 nm, is plotted as a function of the 
"contamination" by the oxidized product (i.e., compound I). 
If stored in a dessicator in the dark, the product (H?-
-pter) remained relatively pure for at least 1 month. 
V.2 SYNTHESIS OF THE COMPOUNDS DESCRIBED IN CHAPTER I I . <t 
V.2.1 й-p.AMINOBENZOXL-PROPIOiïIC ACID (PABP) (COMPOUND 1, 
CHAPTER II.4) 
PABP was obtained by hydrolysis of B-p.acetylaminobenzoyl-
propionic acid (7) in 1 N HCl. The product was purified 
by recrystallization from water, mp.: 185 - 188° dec. Anal.; 
th.: С, 62.16; H, 5-74; Ν, 7-25. f.: С, 62.04; К, 5-72; 
Ν, 7.28. 
V.2.2 ETHYL-(B-p.AMIIWBENZOÏL)-PROPIONATE (COMPOUND В, 
CHAPTER II.4ì 
PABP was converted to the ethylester by refluxing the com-
pound in ethanol containing 155 cone, sulphuric acid. The 
product was recrystallized from benzene-petroleum ether. 
mp.: 91 - 92°. Anal.; th.: С, 65-13; H, 6.83; Ν, 6.33· 
f.: С, 65.25; Η, 6.79; Ν, 6.31. 
V.2.3 a-PHENYL-$-p.AMINOBENZOYL-PROPIONIC ACID AND DERIVATIVES 
ß-p.Aminobenzoyl-propionic acid was obtained by hydrolysis of 
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the corresponding N-acetyl derivative which latter was syn­
thesized from acetanilide and succinic anhydride by the 
Fnedel and Crafts reaction (7). This method seemed useful 
too, to prepare phenyl-substituted derivatives of PAB?. The 
more so s^nce the reaction between an aromate and phenyl-
succinic anhydride at Fnedel and Crafts condition can go in 
two directions leading to either, α-3-disubstituted or 
6-B-disubstituted propionic acids. Deoending on the solvent, 
the reaction can be forced m the one or the other direction 
(21). 
However, no reaction occurred between acetanilide and phenyl-
succinic anhydride at Fnedel and Crafts conditions. Probably, 
the benzene ring m acetanilide is too strongly inactivated 
to enter into an electrophilic substitution reaction with 
the aluminium cj.londe coirplex of phenylsuccinic anhydride. 
The diminished reactivity of acetanilide towards Fnedel and 
Crafts reactions is also shown by Kranzlein (12). o-Phenyl-
-8-p.aninobenzoyl-propionic acid and its derivatives have 
been prepared by hydrogencyanide addition to benzylidene-
-p.acetylaminoacetopnenone (^'-acetylamino-chaleone), 
following the procedure of Davey and Tivey (6) for hydrogen-
cyanide addition to unsubstituted chalcones. 
V.2.3.1 Chalcones 
The chalcones were prepared by the Claisen-Schmidt conaensa-
tion of ρ.acetamidoacetophenone with the corresponding 
benzaldehydes. To a solation of equimolar amounts (0.05 mol) 
of ρ.acetamidoacetophenone and the benzaldehyde in 400 ml 
methanol, 10 ml of a sodium methanolate solution (1 g Na in 
15 ml methanol) was added. The reaction mixture was stirred 
for 24 h at room temperature. The mixture was taken to dry­
ness and the residue was successively treated with water 
and ether. The final residue contained the largest part of 
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the chalcone. An additional fraction was obtained from the 
ether layer. The chalcones were recyrstallized from ethanol-
-water and characterized by IR (+ 167O cm , C=0 amide I; 
-1 -1 
+ 1630 cm , C=0 ketone; +_ I6OO cm , C^C aromate) and by 
elemental analysis (Table V.l). 
Table 
Rl 
H 
Br 
H 
OCH 
H 
: V.l 
CHjCONH^ 
R2 
H 
H 
Br 
H 
OCH, 
1)'-•асе! 
P)ccH=ch 
yield 
90 
75 
85 
60 
90 
% 
tylamino-
•cf«. 
о 
mp 
159-161 
215-217 
162-164 
202-203 
139-1Ί0 
chalcones 
th: 
f: 
th: 
f: 
th: 
f: 
th: 
f: 
th: 
f: 
Ana 
С 
76.95 
76.71 
59-32 
59-СП 
59.32 
58.96 
73.20 
73.14 
73.20 
72.93 
lysis 
Η 
5-69 
5.62 
4.10 
3-93 
4.10 
4.38 
5.80 
5.68 
5.80 
5-89 
Ν 
5.28 
5.33 
4.07 
4.10 
4.07 
4.07 
4.74 
4.67 
4.74 
4.82 
V.2.3.2 1-ρ.Acetylaminophenyl-3-cyano-3-phenyl-propanone-l 
and derivatives 
For the hydrogencyanide addition to the chalcones, the 
following procedure was employed: 
To a solution of 0.01 mol chalcone in 40 ml ethanol, 3 ml 
7 N H.SO^ in 20 ml ethanol was added. The mixture was heated 
to 50 and 0.04 mol NaCN in 5 ml water was added gradually. 
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When all the cyanide was introduced, the mixture was re-
fluxed for 15 min. After stirring for about 16 h at room 
temperature, 20 ml of water was added and the mixture was 
stirred for additional H h. The precipitate was filtered 
and the product was extracted from it with boiling ethanol. 
The crystals, obtained from the ethanol solution after 
chilling, were collected and recrystallized from ethanol. 
The 1-p.acetylaminophenyl-3-cyano-3-phenyl-propanone-l de-
rivatives are listed in Table V.2. 
IR: + 1670 cm" (C=0, amide I, ketone), + I6OO (C=C, aromate) 
Table V.2 
1-p.acetylaniinophenyl-3-cyano-3-phenyl-propanone-l and 
der iva t ives 
CH3CO N H / ^ J \ C CHjÇ H 
Analys i s 
о y i e l d % πφ С Η 
Η 75 141-1^3 t h : 73-95 5-51 9-58 
f: 73.76 5.50 9.42 
para bromo 70 I 6 3 - I 6 5 t h : 58.21 k.07 7-55 
f: 58.18 Ч.18 7.42 
meta bromo 65 ΐ42-1ί)Ί th: 58.24 4.07 7.55 
f: 58.38 4.01 7.56 
para methoxy 40 141-142 th: 70.79 5.63 8.69 
f: 70.71 5.63 8.90 
meta methoxy 70 119-121 th: 70.79 5.63 8.69 
f: 70.38 5-55 8.70 
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ν.2.3·3 o-Phenyl-ß-p.aminobenzoyl-propionic acid and 
derivatives 
The cyano compounds (Table V.2) were converted to the 
corresponding a-phenyl-g-p.aminobenzoyl-propionic acids 
by refluxing in 10% sulphuric acid for k h. The acids were 
isolated by ethylacetate extraction at pH 3.5 and purified 
by recrystallization from ethanol-water (Table V.3). 
-1 -1 
IR: + 1750 cm (C 0, carboxyl group), + 1630 cm (C 0, 
ketone), + I6OO (C C, aromate). 
NMR of a-phenyl-3-p.aminobenzoyl-propionic acid in CF-C00H 
(Varían, 60 MH z): Ar, AA'BB' 7.8 ppm (Ц Pr); Ar, S 7.2 ppm 
(5 Pr); Alif, ABC З.Ч З.9 Ц-Ъ ppm multiplet (3 Pr). 
Table V.3 
o-phenyl-S-p.aminobenzoyl-propionic acid and derivatives 
__ _ ^ R 
H2N<^¿CH2c;H<Qf 
COOH 
p. no hnalysis 
t. II. 1) R yield % mp0 С Η N 
6 H 70 
7 para bromo 60 
8 meta bromo 75 
9 para methoxy 60 
10 meta methoxy 40 
t h : 
f : 
t h : 
f : 
t h : 
f : 
t h : 
f : 
t h : 
f: 
71. 
7 1 . 
55. 
55. 
55, 
55· 
68, 
67. 
68. 
68, 
.HO 
.63 
.19 
.47 
.19 
.22 
.22 
• 70 
.22 
.07 
5.60 
5.89 
H.05 
З.97 
H.05 
1.00 
5.72 
5.69 
5.72 
5.73 
5.19 
5.26 
4.02 
3.96 
11.02 
14.01 
1).68 
Ч.59 
4.68 
4.72 
V.2.Í) (cD-v-PHENÏL-Ü-p.AMINOBEliZOYL-PROPIONIC ACID 
The d-isomer ol' a-phenyl-8-p.aminobenzoyl-propionic acid 
was isolated from the racemate by salt formation with (Z)-
-N-methylchinine hydroxide and repeated crystallization 
from methanol-ether. ((I)-N-methylchinine hydroxide was 
prepared according to Knabe and Kräuter (11)). The d-acid 
was isolated from its salt (mp 213-214°) by treatment with 
2 N HCl and extraction with ethylacetate at pH 3.5, successi-
vely. Starting with 4 g of the racemate, 170 mg of the pure 
isomer was obtained, mp 166 - 168°, (α)ί;0= +112.8° (С = 0.96, 
methanol). 
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SUMMARY 
The aim of the investigation, presented in this thesis, was 
to gather more infornation about the physico-chemical requi­
rements which compounds should fulfil in order to interfere 
with the conversion of p.aminobenzoic acid (РАБА) into dihy-
dropteroic acid (Hp-pteroate) by the enzyme H -pteroate syn­
thetase. The findings thereof may contribute to the design 
of PABA-antagonists which are useful in antiinfectious ther­
apy. In order to avoid permeability effects and/or metabolic 
modification, the (potential) PABA-antagonists were studied 
for their activity in a cell-free Kp-pteroate synthesizing 
enzyme system. 
Chapter I, part 1, describes the biosynthetical pathway of 
H?-pteroate as occurring in microorganisms and plants. The 
methods used in the present investigation, their development 
and justification are described in part two of this chapter. 
Chapter II is dedicated to structure-activity relationships 
of compounds which compete with РАБА for its active site on 
the enzyme. Part one of this chapter deals with sulfonamides. 
The inhibitory activity of these compounds for the cell-free 
Hp-pteroate synthesis shows a parabolic relationship to the 
acidic strength (pK ) of the sulfonamides. This result dis­
proofs the hypothesis that the common observed parabolic de­
pendency between the antibacterial activity of the sulfon­
amides and their acidity is due to permeability factors 
(Breuckner and Cowles). Further, it was shown that the ion­
ized as well as the unionized form of the sulfonamides inter­
act with the active site. The ionized form shows the higher 
affinity. It is concluded that the electrondensity at the 
sulfonylamide moiety of the sulfonamides is determinant for 
the affinity to the enzyme. The observed relationships are 
explainable by the theory of Bell and Roblin. 
Part two deals with derivatives of PABA substituted in the 
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benzene ring. These compounds all show a reduced affinity for 
the enzyme. In general, substitution at the mata position 
with respect to the carboxyl group, is less tolerated than 
substitution at the ortho position. Jsing a model which des­
cribes a linear relation between the biological activity of 
a congeneric series of compounds and thernodynamically re­
lated substituent constants, a quantitative correlation be­
tween the affinity of ortuo-bubst-tuted PABA-denvatives and 
the electronical and stencal parameters of the substituents 
could be evaluated, bydrophobicity appeared not to be signi­
ficant for the interaction. From this quantitative relation, 
on condition the linear description is a correct presunption, 
it can be concluded that stenc hindrance is involved in the 
interaction between the binaing site for РАЗА and the nuclear-
-substituted PABA-denvatives. Further, it is concluded that 
the affinity of tbe corrpounds increases with increasing ion­
ization of the carboxyl group. This might indicate, that an 
ion-ion interaction is involved between the (anti)metabolite 
and the enzyme. 
Part three of this chapter aeals wit1- some para-substituted 
anilines. These compounds were studied in an attempt to ob­
tain information about the role of the aromatic amiro group 
of PABA for the interaction wxth the active site of the en­
zyme. This study revealed the necessity of the p.aminoben-
zoyl radical for the interaction with the PABA binding site. 
The polanzability of the carbonyl group determines the af­
finity of these compounds No clear relation can be observed 
between the activity and the basicity of the aromatic amino 
group. Results obtained with peptide analogs of PABA, г.е., 
p.aminobenzoylglutamic acid and derivatives, suggest the pre­
sence of a stereo-selective accessory binding site which re­
quires (an) acidic function(s) for interaction. 
The fourth part of this chapter, describes the cell-free 
PABA-antagonistic activity of ß-p.aminobenzoyl-propionic acid 
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and derivatives. These compounds were designed on basis of the 
findings of the foregoing parts of this chapter and should, 
because of their structure, interfere with the binding site 
for FABA as well as with the additional binding site. The com-
pounds compete with PABA for the active site on the enzyme. 
The use of (dZ)- and (d)-a-phenyl-ß-p.aminobenzoyl-propionic 
acid clearly showed the stereo-selectivity of the accessory 
binding site. From this approach, however, no useful antibac-
terial compounds can be expected, because the compounds are 
relatively weak antagonists of PABA and they become metabol-
ized to PABA by E.coli. 
Chapter III is dedicated to the enzymic formation of H_-pter-
oate analogs from PABA-derivatives. Evidence is given for the 
formation of the particular H_-pteroate compounds from p.ami-
nosalicylic acid and p.aminohippuric acid. 
Chapter IV is dealing with the question whether inhibitors of 
dihydrofolate reductase also interfere with the enzymic forma-
tion of Hp-pteroate. The reductase as well as the synthetase 
possess binding sites for a dihydropteridine moiety. The cha-
racteristics of these binding sites probably differ largely 
from each other, because no inhibition of the cell-free 
H.-pteroate synthesis from H?-pter and PABA was observed in 
the presence of some of the main antifolates. 
Chapter V, part 1, describes the syntheses, using folic acid 
as starting material, of the 2-amino-4-hydroxypteridines which 
are used as intermediates for the preparation of Hp-pter, the 
pteridine substrate for Hp-pteroate synthesis. 
Part two describes the syntheses of ß-p.aminobenzoyl-propionic 
acid and derivatives, dealt with in chapter II.4. 
In summary, the following conclusions can be put forward: 
The primary aromatic amino group of PABA is important for the 
interaction with the enzyme Hp-pteroate synthetase. The intro-
duction of substituents on it or replacing the group by an-
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other, results in complete loss of affinity. 
heplacinc the benzene nucleus by an isostere group, e.g., 
pyridine, reduces the affinity. 
Substituants in the bezene ring of PABA lowers, probably due 
to steric hindrance, the affinity. 
A free carboxyl group in PABA, which probably is involved in 
an ion-ion interaction, is optical for the interaction with 
the enzyiiie. The polarizability of the carbonyl ь г о иР of com­
pounds, obtained by substitution of the carboxylic-hydroxyl 
group of PABA, determines the affinity. In general, an enhan­
ced electrondensity in the carboxyl (carbonyl) part of the 
PABA molecule, increases the affinity for the enzyme. 
The substitution of the carboxyl group by a sulfonylamide, 
-S0pN<, group seems to be the exception on the rule that 
little or no possibility is given to ¡T.odify tne FA?A molecule 
without losing affinity. Apparently, this group, although 
geometrically less alike a carboxyl group than, for instance, 
a carboxy-amide group, is able to fulfil the electronic re-
quirements necessary for optimal interaction with the active 
site. 
Since only lower forrs of life, i.e., plants and microorga-
nisms, are in possession of the Hp-pteroate synthesizing sys-
tem, this biosystem is an important starting point in the 
development of a selective antiinfectious therapy, which, in 
fact, is realized in the sulfonamides. As far as the sulfon-
amides are concerned, however, it is not likely that pharma-
codynamically more active compounds can be developed than 
those which already are available. Truly it is possible, by 
suitable modulation, to alter the pharmacokinetic properties 
of the sulfonamides. A search for compounds, which interfere 
viith the pteridine substrates involved in the biosynthesis of 
H?-pteroate, right lead to a new class of selective antibac-
terial compounds. 
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SAMENVATTING 
Het doel van het onderzoek, weergegeven in dit proefschrift, 
is het verkrijgen van een beter inzicht in de struktuur-akti-
viteits relaties van para-aminobenzoëzuur-antagonisten. Een 
dergelijk inzicht kan een bijdrage leveren tot het ontwerpen 
van stoffen bruikbaar bij de antiïnfektieuze therapie. Onder-
meer werd nagegaan over welke physisch-chemische eigenschap-
pen een molekuul moet beschikken wil het kunnen interfereren 
met de enzymatische omzetting van ρ.aminobenzoëzuur (PABA) 
in dihydropteroïnezuur (Hp-pteroate). Om permeatie fenomenen 
en of metabole effekten te vermijden, werd het gedeeltelijk 
gezuiverd bakteriëel enzym systeem dat de synthese van H.-pte-
roate uit een pteridine precursor en PABA katalyseert, ge-
bruikt als testsysteem voor het onderzoek. 
Hoofdstuk I, deel 1, geeft een beschrijving van het Hp-pte-
roate synthetiserend biosysteem zoals het onder andere voor-
komt in microorganismen. 
Deel 2 geeft een beschrijving van de voor het onderzoek ge-
bruikte methoden. 
Hoofdstuk II handelt over de relaties tussen physisch-chemi-
sche eigenschappen van enkele groepen van verbindingen en de 
effektiviteit waarmee zij de omzetting van PABA door het en-
zym Hp-pteroate synthetase remmen. 
Deel 1 beschrijft de antagonistische aktiviteit t.o.v. PABA 
van een heterogene serie sulfonamides. Deze vertoont een pa-
rabolische afhankelijkheid van de zuursterkte (pK ) van de 
α 
verbindingen. De waarneming van deze relatie aan het vrije 
enzym systeem pleit tegen de hypothese dat de parabolische re­
latie tussen de antibakteriële aktiviteit van de sulfonamides 
en hun zuursterkte zou berusten op permeabiliteits processen. 
Tevens werd vastgesteld, dat, ofschoon het geïoniseerde sul-
fonamide molekuul de hoogste affiniteit bezit, ook de niet 
geïoniseerde vorm interfereert met de PABA omzetting. De la-
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dingsdichtheid op het sulfonylamide gedeelte van de sulfon-
amides, ook daar waar geen forneel negatieve lading aanwe-
zig is, is zeer waarschijlijk bepalend voor de bindingsinter-
aktie niet het enzym. De gevonden relaties tussen de struktuur 
en aktiviteit van de sulfonamides zijn verklaarbaar met de 
theorie van Bell en Roblin. 
Deel 2 beschrijft de werking van verschillende in de ring ge-
substitueerde derivaten van PABA. Alle verbindingen in deze 
serie vertonen een geringe antagonistische aktiviteit voor de 
PABA omzetting. De verbindingen net een substituent in de or-
tho positie t.o.v. de carboxylgroep blijken werkzamer dan de 
meta gesubstitueerde verbindingen. Uitgaande van een model · 
dat een lineaire relatie beschrijft tussen de biologische ak-
tiviteit binnen een groep van verbindingen en thermodynamisch 
afhankelijke substituent konstanten, werd door middel van 
meervoudige regressie analyse een kwantitatieve relatie ge-
vonden tussen de gemeten Inhibitie Index van ortho gesubsti-
tueerde PABA derivaten enerzijds en de elektronische en ste-
rische parameters van de substituenten anderzijds. De lipo-
filiteit blijkt niet van belang voor de interaktie met het 
vrije enzymsysteem. Uit deze kwantitatieve relatie kan, aan-
nemende dat het uitgangspunt van een lineair model juist is, 
gekonkludeerd worden dat de "active site" waarop PABA gebon-
den wordt, nauw begrensd is voor wat betreft ruimte innemende 
substituenten. Verder blijkt uit deze kwantitatieve relatie, 
dat de affiniteit toeneemt met de ionisatiegraad van de car-
boxylgroep, wat zou duiden op een ion-ion interaktie tussen 
metaboliet, respektievelijk antimetaboliet, en het enzym. 
Deel 3 beschrijft de PABA-antagonistische aktiviteit van een 
aantal para gesubstitueerde aniline derivaten voor het vrije 
enzymsysteem. Deze verbindingen werden bestudeerd in een po-
ging inzicht te krijgen in de rol die de aromatische amino-
groep van het PABA molekuul speelt bij de binding met het en-
zym. Slechts de verbindingen die naast een aromatische amino-
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groep een carbonylgroep pava t.o.ν. de aminogroep bezaten, 
waren in staat de enzymatische PABA omzetting te remmen. Een 
toenemende polariseerbaarheid van de carbonylgroep bleek be­
vorderlijk voor de mate van remming. Een duidelijk verband 
tussen de biologische aktiviteit en de basiditeit van de ami­
nogroep kon niet worden waargenomen. 
De resultaten verkregen met peptide analogen van PABA, т.п. 
ρ.aminobenzoylglutaminezuur en afgeleiden daarvan, gaven aan­
wijzingen voor een additionele bindingsplaats in de buurt van 
de PABA receptor in strikte zin. Deze bindingsplaats vertoont 
een zekere mate van stereo-selektiviteit. Voor interaktie met 
deze bindingsplaats is de aanwezigheid van een of meer vrije 
carboxylgroepen vereist. 
Op basis van de verkregen gegevens, vooral die uit deel 3 van 
dit hoofdstuk, werden verbindingen ontworpen die, op grond 
van hun struktuur, affiniteit zouden moeten vertonen met zo­
wel de bindingsplaats voor PABA als met de genoemde additio­
nele bindingsplaats. Deze verbindingen, gebaseerd op 8-p.ami-
nobenzoyl-propionzuur, beschreven in deel 4 van dit hoofdstuk, 
vertonen een kompetitieve remming van de omzetting van PABA 
door het enzym H.-pteroate synthetase. Met behulp van (dZ)-
en ((i)-a-phenyl-B-p.aminobenzoyl-propionzuur kon stereo-selek­
tiviteit van de veronderstelde additionele bindingsplaats wor­
den aangetoond. Verder bleek dat hydrofobe interaktie geen 
rol speelt bij deze binding. De betrekkelijk geringe affini­
teit van deze stoffen en het feit dat ze door E.coli worden 
afgebroken tot PABA, geeft weinig aanleiding te verwachten dat 
uit dit type van verbindingen bruikbare antibakteriële stoffen 
ontwikkeld kunnen worden. 
Hoofdstuk III handelt over de enzymatische vorming van H2-pte-
roate analogen uit PABA derivaten. De omzetting van p.amino-
salicylzuur en p.aminohippuurzuur in de betreffende dihydro-
pteroïnezuur derivaten wordt beschreven. 
In hoofdstuk IV wordt nagegaan of en in hoeverre dihydrofoli-
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iumzuur reductase remmers interfereren met het Hp-pteroate 
synthetiserend systeem. Zowel het reductase als het "synthe­
tase" bezitten een bindingsplaats voor een dihydropteridine-
groep. De aard van deze bindingsplaats in beide systemen is 
zeer waarschijnlijk sterk verschillend, aangezien verbindingen 
die een sterke affiniteit vertonen voor de dihydropteridine 
bindingsplaats op het reductase, en daardoor de enzymatische 
reduktie blokkeren, geen remming егооггакеп van de Hp-ptero­
ate synthese. 
Hoofdstuk V, deel 1, beschrijft een synthese voor 6-hydroxy-
methylpteridine uit foliumzuur, die, voor wat betreft eenvoud 
en opbrengst, voordelen biedt boven de tot nu toe meest ge­
bruikte methoden. 
Deel 2 beschrijft de methoden gevolgd bij de synthese van de 
in hoofdstuk II.1 genoemde (5-p.aminobenzoyl-propionzuur-deri-
vaten. 
Samenvattend kunnen op grond van de verkregen reultaten de 
volgende konklusies getrokken worden: 
De primaire aromatische aminogroep in het PABA molekuul is van 
belang voor de interaktie met het enzym Hp-pteroate synthetase. 
Verandering van deze groep, hetzij door de introduktie van een 
substituent hetzij door vervanging, resulteert in een volledig 
verlies van de affiniteit voor het enzym. 
Vervanging van de benzeenkern door een isostere groep (b.v. 
pyridine; verlaagt de affiniteit. 
Substitutie in de benzeenring van PABA verlaagt, waarschijn­
lijk tengevolge van sterische hindering, de affiniteit. 
Een vrije carboxylgroep geeft optimale binding met het enzym. 
Waarschijnlijk is de groep betrokken bij een ion-ion interak­
tie tussen PABA en zijn bindingsplaats. Substitutie van de 
carboxyl-hydroxyl-groep reduceert het bindingsvermogen. De ma­
te waarmee de resulterende verbindingen interfereren met het 
enzym wordt mede bepaald door de polariseerbaarheid van de 
carbonylgroep. In het algemeen kan gesteld worden, dat de in-
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teraktie met het enzym wordt bevorderd door een verhoogde 
elektronendichtheid ter plaatse van de carboxyl (carbonyl) 
groep. 
Als uitzondering op de regel dat een verandering in het PABA 
molekuul een vermindering in affiniteit te zien geeft, kan 
genoemd worden de vervanging van de carboxylgroep door een 
sulfonylamide, -SO_N<, groep. Klaarblijkelijk is deze groep, 
ofschoon geometrisch gezien minder verwant aan een carboxyl-
groep dan bijvoorbeeld een carboxy-amide-groep, in staat om, 
hetzij in geïoniseerde dan wel in ongeïoniseerde vorm, aan de 
elektronische eigenschappen te voldoen die vereist zijn voor 
optimale binding. 
Aangezien het Hp-pteroate synthetiserend enzymsysteem, behou-
dens lagere en hogere planten, slechts voorkomt bij nicroor-
ganismen, is dit systeem een belangrijk uitgangspunt voor het 
ontwikkelen van een selektieve antiïnfektieuze therapie, zo-
als in de beschikbare sulfonamides goeddeels gerealiseerd is. 
Op grond van de huidige inzichten is het niet waarschijnlijk, 
dat farmakodynamisch meer aktieve sulfonamides, dan de reeds 
bekende, ontwikkeld kunnen worden. Wel is het mogelijk, door 
modifikatie, de farmakokinetische eigenschappen van het sul-
fonamide in gewenste richting te beïnvloeden. Een verder on-
derzoek naar stoffen die interfereren met de pteridine sub-
straten betrokken bij de biosynthese van H -pteroate, zou we-
gen kunnen openen naar een nieuwe klasse van selektieve anti-
bakteriële middelen. 
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